nct_id,sponsor,start_date,completion_date,study_type,baseline_population,brief_title,official_title,overall_status,phase,enrollment,number_of_arms,interventions
NCT00160407,Hoffmann-La Roche,31-OCT-03,31-DEC-06,Interventional,,Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH),Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH),Completed,Phase 4,50,,Orlistat (Xenical)|1400 kcal diet (30% fat)
NCT00227110,"Takeda Pharmaceuticals North America, Inc.",31-OCT-02,31-JAN-06,Interventional,,Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH),Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH),Completed,Phase 4,55,2,Pioglitazone|Placebo
NCT00303537,Merck Sharp & Dohme LLC,30-NOV-04,30-JUN-08,Interventional,,Metformin in Non-Alcoholic Fatty Liver Disease,"Double Blind, Randomized, Placebo Controlled Trial With Metformin in Non-Alcoholic Fatty Liver Disease (NAFLD)",Unknown status,Phase 2/Phase 3,90,,metformin
NCT00577148,Sanofi,29-FEB-08,28-FEB-09,Interventional,,An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes,"A Double-blind, Randomized, Placebo-controlled, Parallel Group Study of Rimonabant 20 mg Daily for the Treatment of Type 2 Diabetic Patients With Nonalcoholic Steatohepatitis (NASH).",Terminated,Phase 3,89,2,Rimonabant|Placebo (for Rimonabant)
NCT00668070,Astellas Pharma Inc,30-APR-08,31-OCT-10,Interventional,,A Proof-of-principle Study of Oral Treatment of Non-alcoholic Steatohepatitis With a Novel PDE4 Inhibitor ASP9831,"Protocol for a Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, 12-week Treatment, Adaptive Proof-of-principle Study of Twice Daily Oral Dosing of a Novel PDE4 Inhibitor (ASP9831) in Subjects With Non-alcoholic Steatohepatitis (NASH)",Completed,Phase 2,114,3,ASP9831|Placebo
NCT00470171,Axcan Pharma,31-OCT-05,30-NOV-08,Interventional,,Pilot Study of Ursodesoxycholic Acid in Non-Alcoholic Steatohepatitis,Efficacy and Safety of Ursodesoxycholic Acid in the Management of Non-Alcoholic Steatohepatitis,Completed,Phase 2,98,,Ursodesoxycholic acid
NCT00509418,Catalysis SL,28-FEB-07,30-SEP-07,Interventional,,Efficacy and Safety of Viusid in Patients With Nonalcoholic Steatohepatitis,"Efficacy and Safety of Viusid, a Nutritional Supplement, in Patients With Nonalcoholic Steatohepatitis. A Randomized, Controlled and Open Label Study",Completed,Phase 3,60,2,Viusid|Hypocaloric Diet with controlled exercise
NCT00586885,"Ajinomoto USA, INC.",29-FEB-04,30-JUN-06,Interventional,,Effects of Alanine in Patients With Nonalcoholic Steatohepatitis,A Pilot Study: Therapeutic Effect of L-Alanine in Patients With Nonalcoholic Steatohepatitis,Completed,Not Applicable,9,1,L-alanine
NCT00586911,Orphan Medical,31-JAN-03,30-JUN-06,Interventional,,Betaine in Patients With Nonalcoholic Steatohepatitis,"A Randomized, Placebo-Controlled Trial of Betaine in Patients With Nonalcoholic Steatohepatitis (NASH)",Completed,Phase 2,26,2,Cystadane|Identical Placebo
NCT00666016,Hoffmann-La Roche,30-APR-08,30-APR-09,Interventional,,Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 in Patients With Non-Alcoholic Steatohepatitis (NASH),"Double-Blind vs Placebo, Randomized, Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 500 mg QD for One Month in Patients With Non-Alcoholic Steatohepatitis (NASH)",Completed,Phase 2,35,1,TRO19622
NCT00576667,Sanofi,31-JAN-08,28-FEB-09,Interventional,,An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without Diabetes,"A Double-blind, Randomized, Placebo-controlled, Parallel Group Study of Rimonabant 20 mg Daily for the Treatment of Non-diabetic Patients With Nonalcoholic Steatohepatitis (NASH)",Terminated,Phase 3,165,2,Rimonabant|Placebo (for Rimonabant)
NCT00678587,GlaxoSmithKline,30-JUN-08,31-OCT-09,Interventional,,Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures,"Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects With Chronic Liver Disease Undergoing Elective Invasive Procedures",Terminated,Phase 3,292,2,Eltrombopag|Placebo
NCT00794716,Norgine,30-JUN-08,30-NOV-11,Interventional,,Pharmacokinetics of NRL972 in Patients With Nonalcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD),"Prospective Single-centre, Open-label Study to Assess the Pharmacokinetics of Cholyl-lysl-fluorescein (NRL972) in Patients With Clinical Evidence for Non-alcoholic Fatty Liver Disease (NAFLD): Supporting the Disease Staging Into Fatty Liver Disease Versus Non-alcoholic Steatohepatitis (NASH)",Completed,Phase 2,125,1,NRL972
NCT00694746,GlaxoSmithKline,30-JUN-08,31-MAR-14,Interventional,,Study of Fish Oil to Reduce ALT Levels in Adolescents,Randomized Trial of Fish Oil Versus Placebo to Reduce ALT Levels in Overweight Adolescents,Terminated,Phase 1,3,2,Omega-3-acid ethyl esters|Placebo
NCT00680407,Madaus Inc,30-APR-08,30-NOV-12,Interventional,,Phase II Trial of Silymarin for Non-Cirrhotic Patients With Non-Alcoholic Steatohepatitis,"A Multicenter, Randomized, Placebo Controlled Study to Assess the Safety and Efficacy of Orally Administered Silymarin Preparation (Legalon®) for the Treatment of Non-Cirrhotic Patients With Non-Alcoholic Steatohepatitis",Completed,Phase 2,78,3,Placebo|Silymarin 700 mg|Silymarin 420 mg
NCT00706537,Pfizer,31-JUL-08,30-NOV-08,Interventional,,Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH,"A Multiple Dose, Randomized, Double-Blind (3rd Party Open), Placebo-Controlled Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of CP-945598 In Subjects With Nonalcoholic Steatohepatitis (NASH)",Completed,Phase 1,9,2,Active treatment|Placebo
NCT00740610,Gilead Sciences,31-AUG-08,30-SEP-09,Interventional,,"Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)","A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Activity of GS 9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)",Completed,Phase 2,124,5,GS-9450|GS-9450 Placebo
NCT00856869,Norgine,31-AUG-04,30-APR-05,Interventional,,"Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers","A Study in Healthy Volunteers and Patients With Liver Cirrhosis and Non-Alcoholic Steatohepatitis (NASH) to Assess the Effects of Age, Gender, Chronic Liver Disease, and Prandial Effects on the Clearance of Cholyl-Lysyl-Fluorescein (NRL972) an an in-Vivo Marker of Liver Function in Man.",Completed,Phase 1/Phase 2,52,7,NRL972|NRL972|NRL972|NRL972|NRL972|NRL972|NRL972
NCT01094158,Galmed Medical Reserch,30-NOV-10,31-JAN-12,Interventional,,Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis,A Phase II Placebo Controlled Randomised Study of Aramchol on Liver Triglyceride in Patients With Steatosis Due to NAFLD or NASH,Completed,Phase 2,60,3,Aramchol|Aramchol|Placebo
NCT01066364,"Daiichi Sankyo, Inc.",28-FEB-10,29-FEB-12,Interventional,,Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis,Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis,Completed,Phase 2,59,2,Colesevelam Hcl
NCT01154985,"Mochida Pharmaceutical Company, Ltd.",30-JUN-10,31-OCT-12,Interventional,Full Analysis Set,"Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH)","A Phase II Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With NASH",Completed,Phase 2,243,3,Placebo capsule|EPA-E 300 mg capsule|EPA-E 300 mg capsule
NCT00820651,Catalysis SL,30-NOV-09,30-APR-12,Interventional,,Efficacy and Safety of Diamel in Patients With Nonalcoholic Steatohepatitis,"Efficacy and Safety of Diamel, a Nutritional Supplement, in Patients With Nonalcoholic Steatohepatitis. A Randomized and Double Blind Controlled Study",Completed,Phase 3,158,2,Diamel|Placebo and lifestyle counseling
NCT00941642,GlaxoSmithKline,30-SEP-09,30-SEP-12,Interventional,,Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease,Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease,Unknown status,Phase 4,40,2,Lovaza|placebo control
NCT01006889,"Amylin Pharmaceuticals, LLC.",31-JAN-08,28-FEB-10,Interventional,,Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease,A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD),Completed,Phase 4,24,1,Exenatide
NCT01104220,Pfizer,30-APR-10,31-DEC-23,Interventional,,Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk,Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk,Recruiting,Not Applicable,144,6,Weight loss
NCT01237119,Novo Nordisk A/S,31-AUG-10,31-JUL-14,Interventional,,Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis,"48-week Phase II, Randomised, Double Blinded Placebo Controlled Multicentre Trial on Liraglutide's Safety, Efficacy and Action on Liver Histology and Metabolism in Overweight Patients With NASH +/- Type II Diabetes",Completed,Phase 2,52,2,Liraglutide|Liraglutide-placebo
NCT01167088,"Antipodean Pharmaceuticals, Inc.",30-NOV-10,31-JUL-11,Interventional,,A Study to Compare MitoQ and Placebo to Treat Non-alcoholic Fatty Liver Disease (NAFLD),A Double-blind Randomised Placebo-controlled Multicentre Study of 40mg MitoQ and Placebo for the Treatment of Participants With Raised Liver Enzymes Due to Non-Alcoholic Fatty Liver Disease (NAFLD),Terminated,Phase 2,110,2,Mitoquinone mesylate|Placebo
NCT01205087,NasVax Ltd,30-SEP-10,30-APR-11,Interventional,,Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody (mAb)in Patients With the Metabolic Syndrome,Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody in Patients With the Metabolic Syndrome PHASE IIa A Single-blinded Placebo-controlled Clinical Trial,Completed,Phase 2,36,4,OKT3
NCT01244503,Exalenz Bioscience LTD.,28-FEB-11,30-JUN-12,Interventional,Only subjects with metabolic syndrome and suspected non alcoholic fatty liver disease will undergo breath test. They must not have any other liver disease.,Prediction of Severity of Liver Disease by a 13C Octanoate Breath Test (OBT),Prediction of Severity of Liver Disease in Patients With Suspected Nonalcoholic Fatty Liver Disease (NAFLD) by 13C Octanoate Breath Test (OBT),Terminated,Phase 2,61,1,Sodium Octanoate Breath Test
NCT01373554,PharmaKing,31-MAY-11,31-OCT-13,Interventional,,Efficacy and Safety of Oltipraz in the Patients With Non-alcoholic Fatty Liver Disease,"A Multicenter, Randomized, Double-blind, Placebo-controlled, A Multicenter, Randomized, Double-blind, Placebo-controlled, 3 Parallel Groups, Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Oltipraz in Patients With Non-alcoholic Fatty Liver Disease (Except Liver Cirrhosis)",Completed,Phase 2,60,2,Placebo|Oltipraz
NCT01406704,GlaxoSmithKline,31-JAN-04,31-DEC-13,Interventional,,Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH,Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH (Non-alcoholic Steato-hepatitis),Terminated,Phase 4,26,4,Rosiglitazone|alpha-lipoic acid|Rosiglitazone/alpha-lipoic acid
NCT01431521,Merck Sharp & Dohme LLC,26-OCT-11,01-OCT-12,Interventional,,Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008),An Exploratory Study to Evaluate Changes in Hepatic Fat Following Multiple-Dose Administration of MK-4074 and Pioglitazone Hydrochloride,Completed,Phase 1,31,4,MK-4074 200 mg|Placebo for MK-4074|Pioglitazone hydrochloride 30 mg|Placebo for pioglitazone hydrochloride
NCT01277094,Hoffmann-La Roche,30-APR-11,31-MAR-12,Interventional,,A Study of RO5093151 in Patients With Non-Alcoholic Fatty Liver Disease,"Multi-center, Double-blind, Randomized, Placebo-controlled Study of Selective 11 Beta-HSD1 Inhibition With RO5093151 for 12 Weeks to Investigate Efficacy, Safety and Pharmacokinetics of RO5093151 in Non-alcoholic Fatty Liver Disease and Its Metabolic Consequences.",Completed,Phase 1,82,2,Placebo|RO5093151
NCT01278056,"Estimate, GmbH",31-MAR-10,31-JUL-12,Interventional,,The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis,The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis (NASH) - a Prospective Open Label Phase I/II Trial,Completed,Phase 1/Phase 2,5,1,Exjade
NCT01281059,Exalenz Bioscience LTD.,31-JAN-11,,Interventional,,Prediction of Severity of Liver Disease Non Alcoholic Fatty Liver Disease in Patients With Suspected NAFLD by a 13C Octanoate Breath Test,,Unknown status,Not Applicable,,,BreathID - Breath Test - 13C Octanoate
NCT01285362,GlaxoSmithKline,31-MAR-13,30-SEP-14,Interventional,,Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study,Fish Oil for the Treatment of Nonalcoholic Fatty Liver Disease in Children,Completed,Not Applicable,8,2,Fish Oil Supplementation|Placebo Supplementation
NCT01466894,Immuron Ltd.,31-DEC-12,31-DEC-13,Interventional,,Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis,"A Randomized, Double-Blind, Placebo-Controlled Dosing, Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis",Withdrawn,Phase 2,0,3,IMM 124-E|Placebo
NCT01579162,"HepQuant, LLC",31-JAN-12,30-APR-15,Interventional,,Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation,Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation,Completed,Not Applicable,48,5,"Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123)"
NCT01511523,"Biovil Research Group, LLC",31-JAN-12,31-OCT-12,Interventional,,Study to Evaluate the Effect of RGMA001 on Patients With Non Alcoholic Fatty Liver Disease (NAFLD),"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of RGMA001 on Patients With Non Alcoholic Fatty Liver Disease (NAFLD).",Unknown status,Not Applicable,40,2,RGMA001|Sugar Pill
NCT01672866,Gilead Sciences,05-DEC-12,29-DEC-16,Interventional,Safety Analysis Set included all enrolled participants who were randomized and received at least one dose of study drug.,"Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)","A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like Molecule 2 (LOXL2), in Subjects With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)",Terminated,Phase 2,222,3,Placebo|SIM
NCT01680003,Nova Laboratories Sdn Bhd,30-SEP-12,31-DEC-13,Interventional,,Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease,"A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy and Safety of HEPAR-P Capsule for the Treatment of Non-alcoholic Fatty Liver Disease (NAFLD)",Unknown status,Phase 2,50,2,Hepar-P|Placebo for Hepar-P
NCT01703260,AstraZeneca,30-JUN-13,30-SEP-14,Interventional,The randomized set included all participants who were randomized.,Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis,"A Randomized, Double-Blind, Controlled, Multi-Center Phase 2 Study to Evaluate the Effect of Roflumilast Plus Pioglitazone on Liver Enzymes and Liver Fat Content in Subjects With Nonalcoholic SteatoHepatitis",Terminated,Phase 2,20,3,Roflumilast|Pioglitazone|Placebo|Placebo
NCT01694849,Naturalpha|Genfit|Premier Research Group plc,30-SEP-12,31-DEC-15,Interventional,,Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH),"A Multicentre, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GFT505 Once Daily on Steatohepatitis in Patients With Non-Alcoholic Steatohepatitis (NASH).",Completed,Phase 2,270,3,GFT505 80mg|GFT505 120mg|Placebo
NCT01720719,Pfizer,31-MAY-13,31-DEC-16,Interventional,,Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease,An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease,Unknown status,Phase 4,120,2,atorvastatin|Vitamin E
NCT01811472,Novartis Pharmaceuticals,30-JUN-13,30-SEP-14,Interventional,"Full analysis set included patients to whom study treatment was assigned excluding patients who were miss-randomized and did not take investigational drug. Mis-randomized patients were those who were not qualified for randomization, but were inadvertently randomized into the study.","Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients","A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients With Non-alcoholic Fatty Liver Disease",Completed,Phase 2,52,3,LCQ908|placebo
NCT01754714,Abbott|PPD,31-DEC-12,30-SEP-14,Interventional,,Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Fatty Liver Disease and Non-treated Matched Healthy Volunteers as Control Group,"Open-label, Randomized, Parallel-Group, Exploratory Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Steatohepatitis (NASH) and Non-treated Matched Healthy Volunteers as Control Group",Completed,Phase 3,108,4,SAMe 1000 mg|SAMe 1500 mg|SAMe 2000 mg
NCT01919294,Bayer,31-JUL-13,30-JAN-17,Interventional,,Testosterone Replacement in Non-alcoholic Steatohepatitis (TEREPINS),Pilot Open Study of Testosterone Replacement in Non-alcoholic Steatohepatitis,Completed,Phase 2,3,1,testosterone undecanoate
NCT01899859,Galectin Therapeutics Inc.,31-JUL-13,28-FEB-15,Interventional,,Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis,"A Multi-Center, Partially Blinded, Maximum Tolerated Multiple Dose Escalation, Phase 1 Clinical Trial to Evaluate the Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH)With Advanced Hepatic Fibrosis",Completed,Phase 1,31,3,GR-MD-02|Placebo
NCT01985009,Echosens,31-JAN-14,17-JAN-17,Interventional,,"Prospective, Cross-sectional and Multicenter Study, Evaluating the Diagnosis Accuracy of the Controlled Attenuation Parameter(CAP) Measured by FibroScan® (Either With M+ or XL+ Probe) in Patient With Non-Alcoholic Fatty Liver Disease Using Liver Biopsy as Reference.",Evaluating the Diagnosis Accuracy of the Controlled Attenuation Parameter(CAP) Measured by FibroScan® (Either With M+ or XL+ Probe) in Patient With Non-Alcoholic Fatty Liver Disease (NAFLD)Using Liver Biopsy as Reference.,Completed,Not Applicable,450,1,FibroScan® examination.
NCT02006498,Rottapharm,30-JUN-12,31-DEC-15,Interventional,,Silymarin for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD),"A Randomised, Double-blind, Placebo-controlled, Phase II, Single-centre Study to Assess the Safety and Efficacy of Silymarin 700 mg Capsules TID for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)",Completed,Phase 2,99,2,Sillymarin|Placebo
NCT02029586,"Yungjin Pharm. Co., Ltd.",31-JAN-13,30-NOV-14,Interventional,,Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, 12 Weeks, Therapeutic Exploratory Phase 2 Clinical Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease (NAFLD) Except Cirrhosis",Terminated,Phase 2,18,2,MB12066 200mg|Placebo
NCT02174367,Pfizer,30-NOV-12,31-JUL-21,Observational,,An Observational Cohort Study Evaluating Fatty Liver Disease and Liver Fibrosis in Moderate to Severe Psoriasis,An Observational Cohort Study to Evaluate Factors Affecting Prevalence of Fatty Liver Disease and Fibrosis and Factors Affecting Response to Treatment in Patients With Psoriasis,Unknown status,,400,,Transient elastography
NCT02216552,"DSM Nutritional Products, Inc.",31-AUG-15,20-MAR-17,Interventional,,Resveratrol for the Treatment of Non Alcoholic Fatty Liver Disease and Insulin Resistance in Overweight Adolescents,Safety and Efficacy of Resveratrol for the Treatment of Non-Alcoholic Fatty Liver Disease and Associated Insulin Resistance in Overweight and Obese Adolescents,Completed,Phase 2/Phase 3,10,2,Resveratrol|Placebo
NCT02287779,"Mirum Pharmaceuticals, Inc.",19-JAN-15,19-JUN-15,Interventional,Safety analysis set included all participants for whom a randomization number was assigned and who had taken greater than equal (>=) 1 dose of investigational medicinal product (IMP).,Safety and Tolerability Study of SHP626 in Overweight and Obese Adults,"A Randomized, Double-blind, Placebo-controlled, Phase 1 Study to Assess the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Multiple Oral Doses of SHP626 in Overweight and Obese Adult Subjects",Completed,Phase 1,84,2,SHP626|Placebo
NCT02314026,Exalenz Bioscience LTD.,31-MAR-15,30-JUN-17,Interventional,,BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH,Clinical Study of the BreathID® System to Train the Algorithm for the ¹³C-Octanoate Breath Test With or Without the ¹³C-Methacetin Breath Test (OBT and MBT Respectively) for Correlation With Histological Findings Associated With Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases,Completed,Phase 2,140,1,Suspected NASH BreathID test with 13C-Octanoate|Suspected NASH Breath test with 13C Methacetin
NCT01999101,Phenex Pharmaceuticals AG,31-OCT-13,30-JUN-16,Interventional,,Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients,A Safety Pilot Study of Px-104 in Non-alcoholic Fatty Liver Disease (NAFLD) Patients,Completed,Phase 2,12,1,Px-104
NCT02068339,PharmaKing,28-FEB-14,31-MAR-16,Interventional,,Efficacy and Safety of Oltipraz for Liver Fat Reduction in Patients With Non-Alcoholic Fatty Liver Disease Except for Liver Cirrhosis,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Oltipraz for Liver Fat Reduction in Patients With Non-Alcoholic Fatty Liver Disease Except for Liver Cirrhosis",Completed,Phase 3,283,3,Oltipraz 1 (90mg)|Placebo|Oltipraz 2 (120mg)
NCT02077374,Conatus Pharmaceuticals Inc.,31-MAR-14,31-MAR-15,Interventional,,A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases,"A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of IDN-6556 in Subjects With Non-Alcoholic Fatty Liver Disease and Raised Transaminases",Completed,Phase 2,38,2,IDN-6556|Placebo
NCT02279524,"Itamar-Medical, Israel|Galmed Research and Development, Ltd.|ClinIntel|Clinical Reference Laboratory",29-APR-15,22-MAY-18,Interventional,,A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH,"A Phase IIb, Double Blind Randomized, Controlled Clinical Trial, to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH) - Aramchol 005 Study",Completed,Phase 2,247,3,Aramchol
NCT02210715,Merck Sharp & Dohme LLC,31-MAR-15,31-MAR-18,Interventional,,Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients,Randomized Study Comparing Switching to Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Monoinfected Patients Impact on Fatty Liver and Liver Fibrosis Assessed by Noninvasive Diagnostic Methods,Unknown status,Phase 4,58,2,Isentress.|Continue usual antiretroviral therapy
NCT02217475,"Tobira Therapeutics, Inc.",18-SEP-14,22-JUN-17,Interventional,Intent-to-treat (ITT) population included all randomized participants regardless of starting treatment.,Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis,CENTAUR: Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects With Liver Fibrosis,Completed,Phase 2,289,3,Cenicriviroc|Placebo
NCT02354976,AstraZeneca,01-SEP-15,26-MAY-16,Interventional,,A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects.,"A Double-blind Randomized Placebo-controlled, Parallel-group 12 Week Study to Investigate the Effects of Epanova® Compared to Placebo and Compared to Fenofibrate on Liver Fat Content in Hypertriglyceridemic overwEight subjeCTs; EFFECT I",Completed,Phase 2,78,3,Placebo|Omega-3 carboxylic acid|Fenofibrate 200mg|Placebo
NCT02413372,Bristol-Myers Squibb,08-MAY-15,19-JUN-17,Interventional,,A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH),"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-986036 in Adults With Non-alcoholic Steatohepatitis",Completed,Phase 2,184,3,BMS-986036|BMS-986036|Placebo
NCT02443116,"NGM Biopharmaceuticals Australia Pty Ltd|NGM Biopharmaceuticals, Inc",31-JUL-15,17-JAN-20,Interventional,,Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH),"A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group Multiple-center Study With Additional Open-label Single-blind and Placebo-controlled 24-Week Histology Cohorts to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for Up to 24 Weeks in Patients With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)",Completed,Phase 2,254,9,NGM282|Placebo
NCT02421094,Galectin Therapeutics Inc.,30-SEP-15,27-SEP-16,Interventional,,Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis,Phase 2 Study to Evaluate Non-Invasive Imaging Methods in Efficacy Assessment of GR-MD-02 for the Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis,Completed,Phase 2,30,2,GR-MD-02|Placebo
NCT02466516,Gilead Sciences,08-JUN-15,11-OCT-16,Interventional,Safety Analysis Set included all participants who received at least 1 dose of study drug.,"Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3","A Phase 2, Randomized, Open Label Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Subjects With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3",Completed,Phase 2,72,5,SEL|SIM
NCT02316717,Immuron Ltd.,31-DEC-14,30-OCT-17,Interventional,,A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis,"A Phase ll, Randomized, Double-blind, Placebo-controlled Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis.",Completed,Phase 2,133,3,IMM-124E|Placebo
NCT02330549,"Tobira Therapeutics, Inc.",17-JUL-15,08-SEP-16,Interventional,Safety population included all participants who received at least one dose of study drug.,ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLD,ORION - Effect of CCR2 and CCR5 Antagonism by Cenicriviroc on Peripheral and Adipose Tissue Insulin Sensitivity in Adult Obese Subjects With Prediabetes or Type 2 Diabetes Mellitus and Suspected Non-Alcoholic Fatty Liver Disease (NAFLD),Completed,Phase 2,45,2,Cenicriviroc 150 mg|Placebo
NCT02461212,Resonance Health,01-JUL-15,17-MAR-17,Interventional,,Validation of HepaFat-Scan for Noninvasive Measurement of Steatosis in Youth,Validation of HepaFat-Scan for Noninvasive Measurement of Steatosis in Youth,Completed,Not Applicable,50,2,Magnetic Resonance Imaging (MRI)
NCT02605616,AstraZeneca,30-NOV-15,30-SEP-19,Interventional,The overall number of baseline participants does not differ from the number assigned to the arm or comparison group.,Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD),"A Randomized, Double-Blinded, Placebo-controlled Phase IIa Study to Assess the Efficacy and Safety of a Novel AstraZeneca Compound in Subjects With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)",Terminated,Phase 2,93,2,AZ compound|Placebo
NCT02612662,AstraZeneca,24-NOV-15,26-AUG-22,Interventional,,A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects,"A Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4076 Tetracosasodium Following Single-ascending Dose Administration to Healthy Male Subjects","Active, not recruiting",Phase 1,40,6,AZD4076|Placebo
NCT02491905,"Huons Co., Ltd.",30-NOV-13,31-MAY-15,Interventional,,Safety and Efficacy of HL Tablet in Non-alcoholic Fatty Liver Disease Patients,Phase 2 Study to Assess Safety and Efficacy of HL Tablet on Reducing Hepatic Fat in Non-alcoholic Fatty Liver Disease Patients,Completed,Phase 2,69,3,HL tablet|Placebo
NCT02653300,"Oramed, Ltd.",20-SEP-18,01-APR-20,Interventional,,A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH),"An Open-Label Pilot Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Potential of Oral Insulin to Reduce Liver Fat Content and Fibrosis in Patients With Nonalcolholic Steatohepatitis (NASH)",Completed,Phase 2,10,1,Oral Insulin
NCT02571192,"Mirum Pharmaceuticals, Inc.",01-OCT-15,01-OCT-15,Interventional,,A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose,"A Phase 1, Open-label Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of [14C]-SHP626 Following a Single Oral Dose in Healthy Male Subjects",Completed,Phase 1,8,1,SHP626|5.95 μCi RAD
NCT02510599,"Melinta Therapeutics, Inc.",31-DEC-15,28-FEB-17,Interventional,,Safety and Efficacy of Solithromycin in the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis,"An Open Label, Proof of Principle Study to Evaluate the Efficacy and Safety of Solithromycin for the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis",Completed,Phase 2,10,1,solithromycin
NCT02546609,NuSirt Biopharma,19-NOV-15,31-JAN-17,Interventional,Demographic and other baseline characteristics were analyzed using the ITT Population with subjects who met the inclusion criteria.,The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease,"A Randomized, Blinded, Placebo-Controlled Study To Evaluate The Effect Fixed-Dose Leucine, Metformin, Sildenafil Combinations(NS-0200) Versus Placebo On Hepatic Fat Assessed By MRI In Non Alcoholic Fatty Liver Disease Patients",Completed,Phase 2,91,3,Leu-Met-Sil 0.5|Leu-Met-Sil 1.0|Placebo
NCT02548351,Intercept Pharmaceuticals,22-SEP-15,30-SEP-25,Interventional,,Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment,"A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis","Active, not recruiting",Phase 3,2480,3,Obeticholic Acid|Placebo
NCT02574325,Arisaph Pharmaceuticals Inc,31-OCT-15,31-DEC-16,Interventional,,A Study to Assess ARI-3037MO on Hepatic Fat Metabolism in Patients With Dysglycemia and Evidence of Hepatic Steatosis,,Unknown status,Phase 2,11,2,Placebo|ARI-3037MO
NCT02633956,Intercept Pharmaceuticals,04-DEC-15,12-MAR-18,Interventional,,Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL),"A Phase 2, Randomized, Double Blind, Placebo Controlled Clinical Study Investigating the Effects of Obeticholic Acid and Atorvastatin Treatment on Lipoprotein Metabolism in Subjects With Nonalcoholic Steatohepatitis",Completed,Phase 2,84,4,Obeticholic Acid|Atorvastatin|Placebo
NCT02769091,"Teva Branded Pharmaceutical Products R&D, Inc.",30-SEP-16,28-FEB-18,Interventional,,A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes,"A 24-Week, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of 80 mg TEV-45478 Once Daily as Treatment in Adult Patients With Nonalcoholic Steatohepatitis (NASH) Who Also Have Type 2 Diabetes Mellitus - GN",Withdrawn,Phase 2,0,2,TEV-45478|Placebo
NCT02781584,Gilead Sciences,13-JUN-16,17-DEC-20,Interventional,,"Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)","A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)",Completed,Phase 2,220,13,SEL|FIR|CILO|FENO|VAS
NCT02808312,Gilead Sciences,13-JUL-16,16-OCT-18,Interventional,The Safety Analysis Set included all participants who took at least 1 dose of study drug.,Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function,"A Phase 1 Open-Label, Parallel-Group, Adaptive, Single-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of GS-9674 in Subjects With Normal and Impaired Hepatic Function",Completed,Phase 1,57,6,Cilofexor
NCT02637973,Boehringer Ingelheim,31-DEC-15,31-AUG-18,Interventional,,"Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes","Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes",Completed,Phase 4,84,2,Empagliflozin|Placebo
NCT02649465,"Kowa Company, Ltd.",11-NOV-15,30-JUN-21,Interventional,,SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD,Pleiotropic Effects and Safety of Sodium Glucose Co-transporter 2 Inhibitor Versus Sulfonylurea in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver,Completed,Phase 4,40,2,Tofogliflozin|Glimepiride
NCT02654002,Gilead Sciences,20-JAN-16,14-JUL-16,Interventional,The Safety Analysis Set included all randomized participants who took at least 1 dose of study drug. Participants were grouped according to the treatment they actually received.,"Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics","A Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674, and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics",Completed,Phase 1,120,10,Cilofexor|Placebo
NCT02826525,AstraZeneca,18-JUL-16,11-OCT-19,Interventional,,AZD4076 in Type 2 Diabetic Subjects With Non-Alcoholic Fatty Liver Disease.,"Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4076 Following Multiple Ascending Dose Administration to T2DM Subjects With Non-Alcoholic Fatty Liver Disease",Completed,Phase 1,14,2,AZD4076|Placebo
NCT02704403,Genfit,31-MAR-16,28-OCT-20,Interventional,,Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Nonalcoholic Steatohepatitis (NASH) and Fibrosis",Terminated,Phase 3,2157,2,Elafibranor|Placebo
NCT02856555,Gilead Sciences,08-AUG-16,18-JUL-17,Interventional,The Safety Analysis Set included participants who received at least 1 dose of study drug.,"Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis","A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-0976 in Subjects With Nonalcoholic Steatohepatitis",Completed,Phase 2,127,3,Firsocostat|Placebo
NCT02681055,MediciNova,31-MAR-16,01-OCT-19,Interventional,,Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects,"An Open-Label Study To Evaluate The Efficacy, Safety, Tolerability and PK of MN-001 (Tipelukast) on HDL Function and Serum Triglyceride Levels in NASH and Non-Alcoholic Fatty Liver Disease (NAFLD) Subjects With Hypertriglyceridemia",Completed,Phase 2,19,1,MN-001
NCT02686762,Conatus Pharmaceuticals Inc.,26-JAN-16,28-FEB-19,Interventional,,"Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis","A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis",Completed,Phase 2,318,3,Emricasan (5 mg)|Emricasan (50 mg)|Placebo
NCT02784444,"Cirius Therapeutics, Inc.|Chiltern International Inc.",14-SEP-16,30-JUN-19,Interventional,,"A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH","A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)",Completed,Phase 2,392,4,MSDC-0602K|Placebo
NCT02787304,"Mirum Pharmaceuticals, Inc.",24-OCT-16,27-JUL-18,Interventional,,Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH),"A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)",Terminated,Phase 2,197,4,SHP626|Placebo
NCT02891408,Gilead Sciences,23-SEP-16,13-MAY-19,Interventional,The Safety Analysis Set included all participants who took at least 1 dose of study drug.,Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function,"A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-0976 or Fenofibrate in Subjects With Normal and Impaired Hepatic Function",Completed,Phase 1,74,8,Firsocostat|Fenofibrate
NCT02923154,Mitsubishi Tanabe Pharma Corporation,30-SEP-16,30-APR-19,Interventional,,Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH),An Exploratory Study of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH) (Placebo-Controlled Double-Blind Study),Completed,Phase 2,48,2,MT-3995|Placebo
NCT02930161,POLYSAN Scientific & Technological Pharmaceutical Company,30-MAY-16,10-OCT-18,Interventional,,Runihol in Nonalcoholic Fatty Liver Disease and Metabolic Syndrome,Многоцентровое двойное слепое плацебо-контролируемое рандомизированное исследование препарата Рунихол® у пациентов с неалкогольной жировой болезнью печени на фоне метаболического синдрома,Terminated,Phase 2,35,3,Runihol|Placebo
NCT02854605,Gilead Sciences,26-OCT-16,09-JAN-18,Interventional,Safety Analysis Set included all participants who took at least 1 dose of study drug.,"Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)","A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects With Nonalcoholic Steatohepatitis (NASH)",Completed,Phase 2,140,3,GS-9674|Placebo to match GS-9674
NCT02960204,Histogen,17-OCT-16,08-APR-19,Interventional,,"Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension",Completed,Phase 2,263,4,Emricasan|Placebo
NCT03008070,Inventiva Pharma,07-FEB-17,16-MAR-20,Interventional,,Phase 2b Study in NASH to Assess IVA337,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-range, Proof-of-concept, 24-week Treatment Study of IVA337 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)",Completed,Phase 2,247,3,IVA337|IVA337|Placebo
NCT03028740,"Tobira Therapeutics, Inc.",05-APR-17,09-MAR-21,Interventional,Modified Intent-to-Treat (mITT) Population for the Full Study Cohort included participants randomly assigned to a treatment group who received at least one dose of study drug in Parts 1 and 2 of the study combined.,AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH),"AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis",Terminated,Phase 3,1778,2,Placebo|Cenicriviroc
NCT02855164,Novartis Pharmaceuticals,01-AUG-16,06-APR-20,Interventional,"Full analysis set (FAS) was all subjects to whom study treatment had been assigned. Following the intent-to-treat (ITT) principle, subjects were analyzed according to the treatment they have been assigned to at randomization.",Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH),"A Randomized, Double-blind, Placebo Controlled, 3- Part, Adaptive Design, Multicenter Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH): FLIGHT-FXR",Terminated,Phase 2,350,8,Tropifexor (LJN452)|Placebo
NCT02918929,Enanta Pharmaceuticals,30-SEP-16,30-JUN-17,Interventional,,A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD,"A Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study of Orally Administered EDP-305 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (SAD), Multiple Ascending Doses (MAD) and the Effect of Food on EDP-305 Pharmacokinetics in Healthy Subjects, and of Multiple Ascending Doses (MAD) in Subjects With Presumptive NAFLD",Completed,Phase 1,146,4,EDP 305|Placebo
NCT02912260,"Madrigal Pharmaceuticals, Inc.",30-SEP-16,30-APR-18,Interventional,,Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH),"A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-controlled Study of MGL-3196 in Patients With Non-alcoholic Steatohepatitis",Unknown status,Phase 2,125,2,MGL-3196|Placebo
NCT02913105,Novartis Pharmaceuticals,24-OCT-16,19-SEP-18,Interventional,Safety analysis set included all participants that received at least one dose of study drug.,"Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH","A Randomized, Patient and Investigator Blinded, Placebo Controlled, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With Non-alcoholic Steatohepatitis (NASH)",Terminated,Phase 2,122,2,LMB763|Placebo
NCT02923804,Pronova BioPharma,31-OCT-15,01-DEC-17,Interventional,,Evaluation of MF4637 for Correcting the Omega-3 Nutritional Deficiency in NAFLD Patients,"A Randomized, Double-Blind, Placebo-Controlled Evaluation of MF4637 for Correcting the Omega-3 Nutritional Deficiency in NAFLD Patients When Added to Standard of Care",Completed,Not Applicable,172,2,Omega-3|Olive oil
NCT02927184,"Viking Therapeutics, Inc.",28-SEP-16,26-MAR-19,Interventional,,Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess The Efficacy, Safety, and Tolerability of VK2809 Administered for 12 Weeks Followed by a 4-Week Off-Drug Phase in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease",Completed,Phase 2,59,4,VK2809|Placebo
NCT03053063,Gilead Sciences,30-JAN-17,06-MAY-19,Interventional,The Safety Analysis Set included all participants who received at least 1 dose of study drug.,Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH),"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)",Terminated,Phase 3,883,3,SEL|Placebo to match SEL 6 mg|Placebo to match SEL 18 mg
NCT03059446,"Tobira Therapeutics, Inc.",14-FEB-17,05-JAN-21,Interventional,Safety Population included all participants who received at least one dose of study drug.,Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis,Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis (NASH),Terminated,Phase 2,167,1,Cenicriviroc
NCT03060538,"Genentech, Inc.",05-MAR-17,13-DEC-19,Interventional,,A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease,"A Phase Ib, Randomized, Blinded, Placebo-Controlled, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous BFKB8488A in Patients With Type 2 Diabetes Mellitus and Patients With Non-Alcoholic Fatty Liver Disease",Completed,Phase 1,154,2,BFKB8488A|Placebo
NCT03068078,Novo Nordisk A/S,30-NOV-16,04-JUN-21,Interventional,,A Reduced-carbohydrate Diet High in Monounsaturated Fats in Type 2 Diabetes,"A Reduced-carbohydrate Diet High in Monounsaturated Fats in Type 2 Diabetes: a Six-month Study of Changes in Metabolism, Liver- and Cardiovascular Function (ReDuCtion)",Completed,Not Applicable,185,2,Low carbohydrate diet high in monounsaturated fats
NCT02927314,Can-Fite BioPharma,27-NOV-17,01-MAR-20,Interventional,,A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)",Completed,Phase 2,60,3,CF102|Placebo
NCT02941549,Afimmune,24-NOV-16,02-JAN-19,Interventional,The Full Analysis Set (FAS) includes all randomised patients who received at least one administration of study treatment and have at least one post-baseline measurement.,Safety And Efficacy Study Of Orally Administered Epeleuton In Patients With NAFLD,"A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase IIa Study To Assess The Safety And Efficacy Of Orally Administered Epeleuton In NAFLD Patients.",Completed,Phase 2,96,3,Placebo capsules|Epeleuton
NCT02947568,Fresenius Medical Care North America,31-MAR-16,31-DEC-20,Observational,,Genetical Background of Non-alcoholic Fatty Liver Disease (NAFLD) in Diabetes Mellitus and in Chronic Kidney Disease,Genetical Background of Non-alcoholic Fatty Liver Disease (NAFLD) in Diabetes Mellitus and in Chronic Kidney Disease,Unknown status,,600,,non-interventional study
NCT02985450,GlaxoSmithKline,31-AUG-16,31-JAN-21,Observational,7 patients lost to follow-up.,A Prospective Study of HBV Immunity and HBV Vaccination in Patients With NAFLD in Canada,A Prospective Study of Hepatitis B Virus (HBV) Immunity and Hepatitis B Vaccination in Patients With Non Alcoholic Fatty Liver Disease (NAFLD) in Canada,Completed,,82,,Engerix-B
NCT02962297,"R&G Pharma Studies Co.,Ltd.|Zhejiang Medicine Co., Ltd.",31-DEC-16,17-DEC-21,Interventional,,Vitamin E Versus Placebo for the Treatment of Non Diabetic Patients With Nonalcoholic Steatohepatitis,"VENS is a Multicenter, Randomized, Double-masked, Placebo Parallel Controlled Trial to Evaluate the Efficacy and Safety of Treatment With Vitamin E Softgel in Non Diabetic Adults With NASH Compared to Treatment With Placebo in China",Completed,Not Applicable,120,2,Vitamin E softgel|Placebo
NCT02970942,Novo Nordisk A/S,30-NOV-16,19-MAR-20,Interventional,The full analysis set included all randomised participants.,Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.,This Trial is Conducted Globally. The Aim of This Trial is to Investigate Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis,Completed,Phase 2,320,6,Semaglutide|Placebo
NCT02974374,Pfizer,31-OCT-16,31-JAN-17,Interventional,,Single Dose of PF-06835919 Escalation Study in Healthy Adult Subjects,"A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess Safety, Tolerability And Pharmacokinetics Of Single, Escalating, Oral Doses Of Pf-06835919 In Healthy Adult Subjects",Completed,Phase 1,16,2,PF-06835919|Placebo
NCT03143166,Boehringer Ingelheim,22-MAY-17,02-AUG-17,Interventional,Treated set (TS) : All enrolled subjects provided with trial medication and documented to have taken at least 1 dose of trial medication were included in the TS.,Pradaxa Tablet Proton Pump Inhibitor (PPI) Bioavailability (BA) Study in Japan,"Relative Bioavailability of Tablet Formulation of Dabigatran Etexilate With and Without Co-administration of Rabeprazole in Healthy Male Subjects (an Open-label, Single-dose, Two-period, Single-arm Study)",Completed,Phase 1,36,1,Dabigatran Etexilate|Rabeprazol sodium
NCT03163810,Erchonia Corporation,06-FEB-17,13-DEC-17,Interventional,,A Study to See if Low Level Laser Light Therapy (LLLT) Can Improve the Condition of Nonalcoholic Steatohepatitis (NASH),A Pilot Evaluation of the Effect of the Erchonia Verjú™ and EVRL Lasers on Reducing Aminoalanine Transaminase (ALT) in Individuals With Nonalcoholic Steatohepatitis (NASH),Withdrawn,Not Applicable,0,1,Erchonia Verju Laser|Erchonia EVRL Laser
NCT03042767,Immuron Ltd.,01-FEB-17,23-OCT-19,Interventional,,Anti-LPS Antibody Treatment for Pediatric NAFLD,Anti-LPS Antibody in Pediatric Nonalcoholic Fatty Liver Disease,Completed,Phase 2,40,2,IMM-124E|Placebo
NCT03213145,Enanta Pharmaceuticals,11-JUL-17,07-SEP-17,Interventional,,"Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers","A Non-Randomized, Open-Label, Two-Part, Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics and Safety of EDP-305 in Healthy Volunteers",Completed,Phase 1,48,2,intraconazole|Rifampin|EDP 305
NCT03222206,"Kuhnil Pharmaceutical Co., Ltd.",08-NOV-17,22-FEB-19,Interventional,,The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease,"The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study",Completed,Phase 4,34,2,Salsalate|Placebo
NCT03053050,Gilead Sciences,13-FEB-17,19-JUN-19,Interventional,The Safety Analysis Set included all participants who received at least 1 dose of study drug.,Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis",Terminated,Phase 3,808,3,SEL|Placebo to match SEL 6 mg|Placebo to match SEL 18 mg
NCT03061721,Zydus Therapeutics Inc.,06-APR-17,15-DEC-20,Interventional,,Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis,"A Phase 2, Prospective, Multicenter, Double-blind, Randomized Study of Saroglitazar Magnesium 1 mg, 2 mg or 4 mg Versus Placebo in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis",Completed,Phase 2,106,4,Saroglitazar magnesium 1 mg|Saroglitazar magnesium 2 mg|Saroglitazar magnesium 4 mg|Placebos
NCT03294941,"HepQuant, LLC",08-DEC-17,11-SEP-19,Interventional,,The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology,The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology,Terminated,Phase 2,17,1,HepQuant SHUNT Liver Diagnostic Kit
NCT03132662,Neptune,01-JAN-19,01-DEC-19,Interventional,,Omega-3 vs Very Low Calorie Diet for Liver Size Reduction,Comparative Trial of Omega-3 Polyunsaturated Fatty Acids vs a Very Low Calorie Liquid Diet for Liver Volume Reduction Prior to Bariatric Surgery,Unknown status,Not Applicable,60,3,Omega-3|Very Low Calorie Diet
NCT03166735,Boehringer Ingelheim,06-JUN-17,14-JUN-19,Interventional,Treated Set (TS): all patients who signed the informed consent and were treated with at least one dose of the trial medication.,Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH,"A Multi-centre, Double-blind, Parallel-group, Randomised, Placebo Controlled Phase II a Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Different Doses of Orally Administered BI 1467335 During a 12-week Treatment Period Compared to Placebo in Patients With Clinical Evidence of NASH.",Completed,Phase 2,114,5,BI 1467335|Placebo
NCT03198104,Perspectum,01-APR-16,31-MAR-19,Observational,,Assessing Kids for Liver Inflammation and Fibrosis Using Non-invasive MRI,Assessing Kids for Liver Inflammation and Fibrosis Using Non-invasive MRI,Completed,,35,,MRI
NCT03205150,Novartis Pharmaceuticals,04-OCT-17,14-NOV-19,Interventional,,Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients,"A 12-week Randomized, Patient and Investigator Blinded, Placebo-controlled, Parallel Group Study to Investigate the Efficacy of LIK066 in Obese Patients With Non-alcoholic Steatohepatitis (NASH)",Completed,Phase 2,107,3,LIK066|Placebo
NCT03248882,Pfizer,22-AUG-17,27-MAR-19,Interventional,All randomized participants who received at least 1 dose of randomized study treatment.,"Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)","A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, PARALLEL GROUP STUDY TO EVALUATE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-05221304 ADMINISTERED DAILY FOR 16-WEEKS TO ADULT SUBJECTS WITH NONALCOHOLIC FATTY LIVER DISEASE",Completed,Phase 2,305,5,Placebo|PF-05221304
NCT03256526,Pfizer,27-SEP-17,27-APR-18,Interventional,The baseline analysis population included all eligible participants who received the study medication.,6-week Safety and PD Study in Adults With NAFLD,"A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PARALLEL- GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE",Completed,Phase 2,53,3,Placebo|PF-06835919 Low Dose|PF-06835919 High Dose
NCT03261739,"Bird Rock Bio, Inc.|Perspectum",28-AUG-17,24-AUG-18,Interventional,,"Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)","An Adaptive Design Study for the Assessment of the Safety, Tolerability, and Pharmacokinetics of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)",Completed,Phase 1,84,2,RYI-018|Placebo
NCT03289897,Perspectum,04-SEP-17,31-DEC-20,Interventional,,Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan,Non-invasive Rapid Assessment of Non-alcoholic Fatty Liver Disease (NAFLD) Using Magnetic Resonance Imaging With LiverMultiScan (RADIcAL1),Completed,Not Applicable,801,2,LiverMultiScan
NCT03291249,"Tiziana Life Sciences, PLC",01-DEC-17,01-JUN-19,Interventional,,"Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM","A Randomized, Placebo-controlled ,Double-blind, Phase IIa Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)",Withdrawn,Phase 2,0,4,Foralumab|placebo|Omeprazole 20mg
NCT03329885,Bristol-Myers Squibb,02-NOV-17,26-JUN-18,Interventional,"All demographic characteristics for Part A are summarized. Due to early termination of the study, only 1 participant was enrolled in the placebo group and 1 participant in the BMS-986251 group in Part B. Part B demographics data is not reported for privacy reasons.","A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis","A Double-Blind Randomized Placebo-Controlled Single and Multiple Ascending Doses Study of the Safety and Tolerability, Pharmacokinetics (Including Bioavailability Comparison and Food Effect) and Pharmacodynamics of Oral BMS-986251 Administration in Healthy Subjects, With Efficacy Assessment of Multiple Doses in Patients With Moderate-to-Severe Psoriasis",Terminated,Phase 1/Phase 2,38,3,BMS-986251|Placebo
NCT03357380,Novo Nordisk A/S,28-NOV-17,20-MAR-20,Interventional,,A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver,A Trial Investigating the Effect of Subcutaneous Semaglutide on Liver Fibrosis Assessed by Magnetic Resonance Elastography in Subjects With Non-alcoholic Fatty Liver Disease,Completed,Phase 1,67,2,Semaglutide|Placebo
NCT03400163,Bristol-Myers Squibb,08-MAY-15,19-JUN-17,Interventional,,A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH),"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Sub-study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-986036 in Adults With Non-alcoholic Steatohepatitis",Completed,Phase 2,3,2,BMS-986036|Placebo
NCT03439189,Exalenz Bioscience LTD.,28-AUG-16,13-MAY-19,Interventional,"Diagnostic endpoints used screening measurements taken prior to study drug administration, therefore no treatment effect was relevant. In addition, for the event prediction endpoints, the treatment covariate was tested for significance, and was found to be non-significant, thus removed from the final predicting model. As such, arms were combined.",Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14,"Companion Protocol for the ¹³C-Methacetin Breath Test Using the BreathID® MCS System for Conatus Phase 2 Study of Emricasan, an Oral Caspase Inhibitor, Under Protocol IDN-6556-14 (NCT02960204)",Completed,,343,4,Methacetin Breath Test|Emricasan|Placebo oral capsule
NCT03468556,Sinew Pharma Inc.,01-DEC-22,30-DEC-23,Interventional,,"A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis","A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis",Not yet recruiting,Phase 2,80,2,SNP-610|Placebo Oral Tablet
NCT03371355,"Ionis Pharmaceuticals, Inc.|Akcea Therapeutics",21-DEC-17,24-FEB-20,Interventional,Full Analysis Set (FAS) population included all participants who were randomized and received at least 1 dose of study drug.,"Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease","A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Finding Study of ISIS 703802 (AKCEA-ANGPTL3-LRx) Administered Subcutaneously to Subjects With Hypertriglyceridemia, Type 2 Diabetes Mellitus (T2DM), and Nonalcoholic Fatty Liver Disease (NAFLD)",Completed,Phase 2,105,4,Placebo|ISIS 703802 40 mg|ISIS 703802 80 mg|ISIS 703802 20 mg
NCT03479125,Conatus Pharmaceuticals Inc.,27-FEB-18,30-SEP-19,Observational,,Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo,Protocol IDN-6556-18 - A Post Treatment Follow-up Study for Liver Disease Subjects With or Without Liver Cirrhosis After Receiving Emricasan or Placebo,Terminated,,40,,Ultrasound
NCT03513588,Pfizer,21-JUN-18,04-APR-19,Interventional,All randomized participants who received at least 1 dose of study treatment (PF-06865571 or placebo).,2-Week Study In People With Nonalcoholic Fatty Liver Disease,"A PHASE 1B, RANDOMIZED, DOUBLE-BLIND (SPONSOR-OPEN), PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACODYNAMICS AND PHARMACOKINETICS OF MULTIPLE ORAL DOSES OF PF- 06865571 FOR 2 WEEKS IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE",Completed,Phase 1,48,3,Placebo|PF-06865571|PF-06865571
NCT03536650,"Fractyl Laboratories, Inc.",08-NOV-17,31-DEC-20,Interventional,,Effect of DMR in the Treatment of NASH,"Evaluation of Duodenal Mucosal Resurfacing (DMR) for the Treatment of Non Alcoholic Steatohepatitis (NASH), a Proof of Concept Study",Completed,Not Applicable,14,1,DMR
NCT03551522,"CymaBay Therapeutics, Inc.",30-APR-18,10-AUG-20,Interventional,,A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH),"A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Followed by an Open-Label Extension Period to Evaluate the Activity of Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)",Terminated,Phase 2,181,5,Seladelpar|Placebos|Seladelpar
NCT03332940,Navidea Biopharmaceuticals,06-DEC-17,10-MAR-19,Interventional,,An Evaluation of the Safety of Intravenous Tc 99m Tilmanocept and a Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH,An Evaluation of the Safety of Intravenous (IV) Tc 99m Tilmanocept and a Comparison of Localization to Tc 99m Sulfur Colloid in Subjects With Nonalcoholic Steatohepatitis (NASH) and Healthy Controls (HC),Completed,Phase 1,6,1,Tc 99M Sulfur Colloid|Tc99m-tilmanocept
NCT03350165,"Kowa Company, Ltd.",27-DEC-17,30-JUN-20,Interventional,,A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease.",Completed,Phase 2,118,2,K-877|Placebo
NCT03392779,"Guangdong Zhongsheng Pharmaceutical Co., Ltd.",05-JAN-18,22-MAR-19,Interventional,,"Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP1601, and the Effect of Food on ZSP1601 Pharmacokinetics","A Phase 1 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ZSP1601 and the Effect of Food on ZSP1601 Pharmacokinetics in Chinese Healthy Subjects.",Completed,Phase 1,94,9,ZSP1601 25 mg|Placebo 25mg|ZSP1601 50 mg|Placebo 50 mg|ZSP1601 100 mg|Placebo 100 mg|ZSP1601 175 mg|Placebo 175 mg|ZSP1601 275 mg|Placebo 275 mg|ZSP1601 350 mg|Placebo 350mg|ZSP1601 100 mg|Placebo 100mg|ZSP1601 50 mg|Placebo 50 mg|ZSP1601 100 mg|Placebo 100 mg
NCT03439254,Intercept Pharmaceuticals,30-AUG-17,31-AUG-22,Interventional,,Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis,"A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis","Active, not recruiting",Phase 3,919,3,Obeticholic acid (10 mg)|Obeticholic acid (10 mg to 25 mg)|Placebo
NCT03421431,Enanta Pharmaceuticals|ICON Clinical Research,25-APR-18,10-JUL-19,Interventional,"Demographics were summarized for the Safety Population, which included all the randomized participants who received at least one dose of the study treatment.

The numbers of participants included in the Efficacy Population were same as the Safety Population.","A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis","A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)",Completed,Phase 2,134,3,EDP-305 Dose 1|EDP-305 Dose 2|Placebo
NCT03437720,Sanofi,23-MAY-19,25-AUG-21,Interventional,,Assessment of the Safety and Effect of SAR425899 Versus Placebo for the Treatment of Non-alcoholic Fatty Liver Disease,"A 52-week Double-blind, Randomized, Placebo-controlled, Phase 2 Study to Assess the Efficacy and Safety of SAR425899 for the Treatment of Non-alcoholic Steatohepatitis (NASH)",Withdrawn,Phase 2,0,4,SAR425899|Placebo
NCT03445208,Bristol-Myers Squibb,14-FEB-18,02-MAY-18,Interventional,,A Study of Experimental Medication BMS-986036 Given to Healthy Participants,"An Open-Label, Single-Dose, Fixed-Sequence Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986036 Administered to the Abdomen and Upper Arm in Healthy Participants",Completed,Phase 1,30,3,BMS-986036
NCT03610945,Enanta Pharmaceuticals,19-JUL-18,21-AUG-18,Interventional,,"Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers","A Non-Randomized, Open-Label, Two-Part, Drug-Drug Interaction Study to Evaluate the Effects of Fluconazole and Quinidine on the Pharmacokinetics and Safety of EDP-305 in Healthy Volunteers",Completed,Phase 1,48,2,Fluconazole|Quinidine|EDP-305|EDP-305
NCT03449446,Gilead Sciences,21-MAR-18,19-NOV-19,Interventional,The Safety Analysis Set included all participants who took at least 1 dose of study drug.,"Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)","A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)",Completed,Phase 2,395,7,SEL|FIR|CILO|Placebo to match FIR|Placebo to match CILO|Placebo to match SEL
NCT03486912,Bristol-Myers Squibb,12-JUN-18,14-SEP-21,Interventional,,A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis,"A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults With Nonalcoholic Steatohepatitis (NASH) and Compensated Liver Cirrhosis",Completed,Phase 2,152,4,BMS-986036|Placebo
NCT03648554,Eli Lilly and Company,01-SEP-19,30-MAR-24,Interventional,,Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST),A Multicentre Controlled and Randomized Study Assessing the Effect of Dulaglutide add-on to Dietary Reinforcement Versus Dietary Reinforcement Alone in Patients With Type 2 Diabetes and Carriers of a Non-alcoholic Steatohepatitis,Not yet recruiting,Phase 4,93,2,dulaglutide (TRULICITY®) 1.5 mg|reinforced dietary monitoring
NCT03664596,Eurasia Invest Ltd.,01-AUG-18,01-DEC-20,Interventional,,Therapeutic And Dietary Effects Of The Sublimated Mare's Milk Supplement In Patients With Non-Alcoholic Steatohepatitis,Evaluation Of The Therapeutic And Dietary Properties Of The Sublimated Mare's Milk Supplement In Patients With Non-Alcoholic Steatohepatitis,Completed,Not Applicable,80,3,Sublimated mare's milk|Ursodeoxycholic Acid
NCT03674528,Siemens Medical Solutions|GE Healthcare|Pfizer,04-MAY-18,01-MAY-23,Observational,,Technical Validation of MR Biomarkers of Obesity-Associated NAFLD,Technical Validation of Magnetic Resonance Biomarkers of Obesity-Associated Non-Alcoholic Fatty Liver Disease,Recruiting,,145,,Magnetic Resonance Elastography (MRE)|Liver biopsy
NCT03459079,Inventiva Pharma,14-AUG-18,30-APR-22,Interventional,,Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease,"Efficacy, Safety and Mechanism of Action of Lanifibranor (IVA337) in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease",Recruiting,Phase 2,44,2,Lanifibranor|Placebo
NCT03486899,Bristol-Myers Squibb,19-JUN-18,17-AUG-21,Interventional,,A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis,"A Phase 2B Randomized Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis",Completed,Phase 2,191,4,BMS-986036|Placebo
NCT03517540,Allergan|Novartis Pharmaceuticals,11-SEP-18,15-OCT-20,Interventional,"Full analysis set (FAS) - All participants to whom study treatment was assigned (excluding patients who were mis-randomized and did not take investigational drug. Mis-randomized participants were those who were not qualified for randomization but were inadvertently randomized into the study). Following the intent-to-treat (ITT) principle, patients were analyzed according to the treatment they had been assigned to at randomization.","Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis","A Randomized, Double-blind, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of a Combination Treatment of Tropifexor (LJN452) and Cenicriviroc (CVC) in Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis",Completed,Phase 2,193,4,Tropifexor (LJN452)|Cenicriviroc (CVC)
NCT03681457,Novartis Pharmaceuticals,24-SEP-18,25-SEP-19,Interventional,,"Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects","A Phase 1, Open-label, Single-dose, Multi-center, Parallel Group Study to Evaluate the Pharmacokinetics of Tropifexor (LJN452) in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Control Subjects",Completed,Phase 1,42,4,LJN452
NCT03538236,ReShape Lifesciences,01-MAR-21,30-MAY-22,Interventional,,Intragastric Balloon With Lifestyle Intervention vs. Lifestyle Intervention in Obese Patients With NASH,Intragastric Balloon in Combination With Lifestyle Intervention vs. Lifestyle Intervention Alone in Obese Patients Having NASH With Significant Fibrosis,Withdrawn,Not Applicable,0,2,Intragastric balloon|Lifestyle intervention
NCT03617263,Zydus Therapeutics Inc.,04-DEC-18,31-MAR-23,Interventional,,Saroglitazar Magnesium 4 mg in the Treatment of NAFLD in Women With PCOS (EVIDENCES VII),"Phase 2A, Double-blind, Randomized, Controlled Clinical Trial to Evaluate the Efficacy and Safety of Saroglitazar Mg 4 mg Tablet Vs Placebo for Treating NAFLD in Women With Polycystic Ovary Syndrome (PCOS)",Recruiting,Phase 2,90,2,Saroglitazar Magnesium 4 mg Tablet|Placebo
NCT03744182,Hanmi Pharmaceutical Company Limited,01-NOV-18,18-MAR-20,Interventional,,A Study of Multiple Doses of HM15211 in Obese Subjects With NAFLD,"A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of HM15211 in Obese Subjects With NAFLD",Completed,Phase 1,66,2,HM15211|Placebo of HM15211
NCT03593343,Unilever R&D,08-JAN-19,13-JAN-20,Interventional,,Hepatic Glycogen and Fat Oxidation,The Effect of Modulating Hepatic Glycogen Content on Hepatic Fat Oxidation,Completed,Not Applicable,11,2,Overnight fasting duration
NCT03604016,IlDong Pharmaceutical Co Ltd,23-SEP-18,30-JUL-20,Interventional,,Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver,Pilot Study to Assess the Antiviral Activity and Safety of Besifovir Dipivoxil 150mg and L-carnitine 660mg Compared to Tenofovir Alafenamide 25mg in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver,Unknown status,Phase 4,76,2,Besifovir dipivoxil|L-carnitine|Tenofovir Alafenamide
NCT03625284,Algatechnologies Ltd.,10-SEP-18,10-DEC-19,Interventional,,Oral Dietary Fucoxanthin Rich Supplement for Liver Health,Oral Dietary Fucoxanthin Rich Supplement for Liver Health,Unknown status,Not Applicable,30,2,Placebo|FucoVital
NCT03627819,Unilever R&D|Raisio Group|BASF,04-MAY-18,31-DEC-19,Interventional,,Plant Sterols and Plant Stanols and Liver Inflammation,The Effects of Plant Sterol and Plant Stanol Ester Enriched Foods on Biopsy Proven Liver Inflammation in NAFLD Patients - a Proof-of-concept Pilot Study,Unknown status,Not Applicable,15,3,Plant sterol-enriched margarine|Plant stanol-enriched margarine|Control margarine
NCT03639623,Zydus Therapeutics Inc.,25-FEB-19,30-JUN-22,Interventional,,"Safety, Tolerability and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With NAFLD","A Phase 2A, Single Center, Open-label, Single-arm, 24-week Study to Evaluate the Safety, Tolerability and Efficacy of Saroglitazar Magnesium 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (EVIDENCES VIII)",Recruiting,Phase 2,15,1,Saroglitazar
NCT03868566,Sinew Pharma Inc.,04-AUG-17,31-DEC-21,Interventional,,"An Open-Label Study to Assess the Hepatic Protection Effect of SNP-612, in Patients With NAFLD","An Open-Label Study to Assess the Hepatic Protection Effect of a Food Supplement Product, SNP-612, in Patients With Non-alcoholic Fatty Liver Disease",Unknown status,Not Applicable,72,4,SNP-612 dose1|SNP-612 dose2|SNP-612 dose3|SNP-612 placebo
NCT03743272,Perspectum,03-JUN-17,01-NOV-22,Observational,,Repeatability and Reproducibility of Multiparametric MRI,Repeatability and Reproducibility of Multiparametric MRI (LiverMultiScan),Recruiting,,61,,LiverMultiScan
NCT03950882,Poxel SA,01-AUG-19,31-MAR-20,Interventional,,A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD,"A Randomized, Double-blind, Placebo-controlled Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)",Completed,Phase 1,17,2,PXL770|Placebo
NCT03969719,Pfizer,18-JUL-19,30-MAR-21,Interventional,,A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus,"A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PARALLEL GROUP STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED DAILY FOR 16 WEEKS IN ADULTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND TYPE 2 DIABETES MELLITUS ON METFORMIN",Completed,Phase 2,164,3,Placebo|PF-06835919|PF-06835919
NCT03976687,Enyo Pharma,11-JUN-19,25-MAY-20,Interventional,,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EYP001a in Healthy Volunteers and Nonalcoholic Steatohepatitis Patients","A Phase 1b, Open-label Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FXR Agonist/Modulator EYP001a in Healthy Volunteers and Nonalcoholic Steatohepatitis Patients",Completed,Phase 1,16,3,EYP001a
NCT03987074,Novo Nordisk A/S|Gilead Sciences,29-JUL-19,13-JUL-20,Interventional,The Safety Analysis Set included participants who received at least 1 dose of study drug.,"Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)","A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)",Completed,Phase 2,109,5,Semaglutide|Firsocostat|Cilofexor
NCT04052516,NorthSea Therapeutics B.V.,17-JUL-19,30-JAN-23,Interventional,,A Phase 2b Study of Icosabutate in Fatty Liver Disease,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of NST-4016 in Patients With Nonalcoholic Steatohepatitis (NASH)","Active, not recruiting",Phase 2,280,3,Icosabutate|Placebo
NCT03656744,HighTide Biopharma Pty Ltd,26-NOV-18,09-MAR-20,Interventional,"One-hundred one subjects were randomized into the study, however, subject did not receive investigational study drug and was not included in the efficacy or safety analyses data sets.",A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM),A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adults With NASH and T2DM,Completed,Phase 2,101,3,HTD1801|Placebo
NCT03674476,Bristol-Myers Squibb,11-SEP-18,24-JUN-19,Interventional,,An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function,"A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986036 in Participants With Varying Degrees of Renal Function",Completed,Phase 1,40,4,BMS-986036
NCT03676231,Second Genome,18-JAN-19,01-MAY-19,Interventional,,Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH),"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SGM-1019 Administered for 12 Weeks in Subjects With F1-F3 Nonalcoholic Steatohepatitis (NASH)",Terminated,Phase 2,9,3,SGM-1019|Placebo
NCT03748628,Enanta Pharmaceuticals,05-OCT-18,13-OCT-18,Interventional,,"Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects","A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]EDP-305 Following a Single Oral Dose in Healthy Male Subjects",Completed,Phase 1,8,1,EDP-305
NCT03776175,Pfizer,04-JAN-19,11-OCT-19,Interventional,Safety analysis population included all participants who received at least 1 dose of investigational product post-randomization.,"A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.","A PHASE 2A, RANDOMIZED, DOUBLE BLIND (SPONSOR-OPEN), PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE PHARMACODYNAMICS, SAFETY AND TOLERABILITY OF PF-05221304 AND PF-06865571 CO-ADMINISTERED FOR 6 WEEKS IN ADULTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)",Completed,Phase 2,99,4,PF-05221304 Monotherapy|PF-06865571 Monotherapy|Placebo|PF-05221304 and PF-06865571 Combination
NCT03763877,Poxel SA,29-MAR-19,10-AUG-20,Interventional,"Intent to treat set (ITTS), defined as all as-randomized patients who received at least one dose of study treatment.",A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD,"A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Assess the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD",Completed,Phase 2,121,4,PXL770|Placebo Oral Capsule
NCT03783897,Enanta Pharmaceuticals|Covance,27-NOV-18,18-JUN-19,Interventional,,A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects,"A Phase 1, Open-label, Fixed-sequence Study to Investigate the Effects of EDP 305 on the Pharmacokinetics of a Combined Oral Contraceptive in Healthy Adult Female Subjects",Completed,Phase 1,43,1,EDP-305|Oral Contraceptive
NCT04104321,"Galmed Research and Development, Ltd.",23-SEP-19,30-JUN-27,Interventional,,A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR),"A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With Nonalcoholic Steatohepatitis (NASH) With Open-Label Part to Evaluate the Safety, PK and Treatment Response Kinetics of Aramchol. The ARMOR Study",Recruiting,Phase 3,2000,2,Aramchol|Placebo
NCT04137055,"Guangdong Raynovent Biotech Co., Ltd",19-NOV-19,09-DEC-20,Interventional,,"Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP0678, and the Effect of Food on ZSP0678 Pharmacokinetics","A Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ZSP0678 and the Effect of Food on ZSP0678 Pharmacokinetics in Chinese Healthy Subjects.",Completed,Phase 1,104,11,ZSP0678-10mg|ZSP0678-30mg|ZSP0678-60mg|ZSP0678-120mg|ZSP0678-180mg|ZSP0678-240mg|ZSP0678-320mg|ZSP0678|ZSP0678-Dose 1|ZSP0678-Dose 2|ZSP0678-Dose 3|ZSP0678 Placebo
NCT03900429,"Madrigal Pharmaceuticals, Inc.",28-MAR-19,31-MAR-24,Interventional,,A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis,"A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (Resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation",Recruiting,Phase 3,2000,3,MGL-3196|Placebo
NCT04171765,"Genentech, Inc.",30-SEP-20,12-JAN-23,Interventional,,"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis","A Phase II, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Patients With Non-Alcoholic Steatohepatitis","Active, not recruiting",Phase 2,260,6,Placebo|BFKB8488A
NCT04173065,"Viking Therapeutics, Inc.",15-NOV-19,31-DEC-22,Interventional,,A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH,"VK2809 A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of VK2809 Administered for 52 Weeks Followed by a 4-Week Off-Drug Phase in Subjects With Biopsy Proven Non-Alcoholic Steatohepatitis With Fibrosis",Recruiting,Phase 2,337,5,VK2809|Placebos
NCT04267393,Bristol-Myers Squibb,17-MAR-21,23-JUL-24,Interventional,,Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH),"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Phase 2 Study to Evaluate the Efficacy and Safety of BMS-986263 in Adults With Compensated Cirrhosis From Nonalcoholic Steatohepatitis (NASH)",Recruiting,Phase 2,270,3,BMS-986263|Placebo
NCT04341246,Perspectum,28-JAN-21,31-AUG-22,Observational,,Characterization and Technical Evaluation of cT1 for NASH (CATE-NASH),Characterization and Technical Evaluation of cT1 for NASH (CATE-NASH): A Case-control Study,Recruiting,,60,,LiverMultiscan
NCT03801577,BASF AS,28-FEB-19,31-DEC-19,Interventional,,Hepaxa Management of Non-alcoholic Fatty Liver Disease,Hepaxa Management of Non-Alcoholic Fatty Liver Disease (NAFLD): A Real-world Pilot Study Observing Effects of Nutritional Management With Hepaxa in Subjects With Liver Steatosis,Unknown status,Not Applicable,50,1,Hepaxa
NCT03812029,Enyo Pharma,30-JAN-19,06-JUL-21,Interventional,,"Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)","A Phase 2a, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis",Completed,Phase 2,120,5,EYP001a|Placebo
NCT03823703,Corcept Therapeutics,04-NOV-20,05-APR-21,Interventional,,"Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)","A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)",Terminated,Phase 2,12,3,Miricorilant|Miricorilant|Placebo
NCT03863574,Zydus Therapeutics Inc.,12-JUN-19,30-OCT-20,Interventional,,Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis,"A Phase 2, Prospective, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 2 mg and 4 mg in Patients With Non-alcoholic Steatohepatitis",Completed,Phase 2,16,3,Saroglitazar Magnesium 2mg|Saroglitazar Magnesium 4mg|Placebos
NCT03883607,Genfit,25-JUN-19,16-JUN-20,Interventional,Analysis was performed on intent-to-treat (ITT) population that had included participants who were randomized and had received at least 1 dose of the study drug.,"Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)","An Open Label, Randomized, Multicenter Study to Assess the Pharmacokinetic and Pharmacodynamic Profile and the Safety and Tolerability of Two Dose Levels of Elafibranor (80 mg and 120 mg) in Children and Adolescents, 8 to 17 Years of Age, With Nonalcoholic Steatohepatitis (NASH)",Terminated,Phase 2,10,2,Elafibranor 80mg|Elafibranor 120mg
NCT03912532,"NGM Biopharmaceuticals, Inc",16-MAY-19,29-MAR-21,Interventional,,"Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)","A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Three Doses of NGM282 Administered for 24 Weeks for the Treatment of Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)",Completed,Phase 2,171,4,NGM282|Placebo
NCT03910361,"Dong-A ST Co., Ltd.",12-APR-19,02-JUL-20,Interventional,,Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases,"A Multicenter, Double-blind, Active-controlled, Randomized, Parallel, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Evogliptin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases",Completed,Phase 4,51,2,Evogliptin|Pioglitazone
NCT04378010,Enanta Pharmaceuticals,27-JAN-20,31-DEC-22,Interventional,,"A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH","A Phase 2b Randomized, Double Blind, Placebo-Controlled, Multicenter Study Evaluating Safety and Efficacy of EDP-305 in Subjects With Liver Biopsy Proven Non-Alcoholic Steatohepatitis (NASH) (ARGON-2)",Recruiting,Phase 2,336,3,EDP-305 1.5 mg|EDP-305 2 mg|Placebo
NCT03963921,Promethera Therapeutics,09-APR-19,31-AUG-20,Interventional,,Safety and Tolerability of HepaStem in Patients With Cirrhotic and Pre-cirrhotic NASH Patients,"Multicenter, Open-label, Safety and Tolerability Study of Ascending Doses of HepaStem in Patients With Cirrhotic and Pre-cirrhotic Non-alcoholic Steato-hepatitis (NASH)",Completed,Phase 1/Phase 2,23,2,HepaStem
NCT04389775,"Sciwind Biosciences APAC CO Pty. Ltd.|Hangzhou Sciwind Biosciences Co., Ltd.",29-MAR-20,29-SEP-21,Interventional,,"To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants","A Phase 1, Randomised, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XW003 Injection in Healthy Adult Participants",Completed,Phase 1,64,4,Cohort A|Placebo A|Cohort B|Placebo B
NCT04399538,Pfizer,10-AUG-20,28-SEP-22,Interventional,,Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis,"A PHASE 2A, 2-PART, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY PLACEBO-CONTROLLED, PARALLEL-GROUP (SPONSOR OPEN) STUDY TO ASSESS PHARMACODYNAMICS AND SAFETY OF PF-06865571 (DGAT2I) COADMINISTERED WITH PF-05221304 (ACCI) IN ADULT PARTICIPANTS WITH PRESUMED NONALCOHOLIC STEATOHEPATITIS (NASH)",Recruiting,Phase 2,180,5,PF-06865571|PF-05221304|Placebo
NCT04422496,"Sunshine Lake Pharma Co., Ltd.",10-AUG-20,23-FEB-21,Interventional,,"The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Subjects","A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Clinical Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HEC96719 Tablets in Healthy Subjects",Completed,Phase 1,73,2,HEC96719
NCT04462562,Samsung Medison,03-JUL-20,29-JUN-21,Interventional,,Quantitative US for Evaluation of Hepatic Steatosis in NAFLD,The Diagnostic Performance Assessment of Quantitative Ultrasound Imaging Indices for Differentiating Hepatic Steatosis Grade in Patients With Non-alcoholic Fatty Liver Disease,Completed,Not Applicable,173,1,"Quantitative US (Samsung Medison, RS85A)"
NCT03938246,Sagimet Biosciences Inc.,22-MAR-19,02-OCT-21,Interventional,,Study of TVB 2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH),"A Phase 2, Multi-Center, Single-Blind, Randomized, Placebo-Controlled Study of TVB 2640 in Subjects With Non-Alcoholic Steatohepatitis (FASCINATE-1)",Completed,Phase 2,142,3,TVB-2640|Placebo
NCT03953456,Genfit,16-AUG-19,14-JUL-20,Interventional,,Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL),"A Double-Blind, Placebo-Controlled, Cross-over Phase II Study to Evaluate the Effect of a 6-week Elafibranor (120mg) Treatment Administered Once Daily on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)",Terminated,Phase 2,17,2,elafibranor 120mg|Placebo
NCT03962608,Yaqrit Ltd,31-JAN-21,31-JAN-21,Interventional,,Safety and Tolerability of Yaq-001 in Patients With Non-Alcoholic Steatohepatitis,"Safety and Tolerability of Yaq-001 in Patients With Non-Alcoholic Steatohepatitis (""NASH-Safety"")",Withdrawn,Not Applicable,0,2,Yaq-001|Placebo
NCT03970031,"Cirius Therapeutics, Inc.",30-JUN-22,30-SEP-24,Interventional,,A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH,"MMONARCh-1: Study of MSDC-0602K, a Modulator of the Mitochondrial Pyruvate Carrier for Outcomes in Patients With Pre Type 2 Diabetes (T2D) or T2D and NAFLD/NASH, Assessed for ImpRoved Glycemic Control and Cardiovascular Outcomes-1",Not yet recruiting,Phase 3,1800,2,MSDC-0602K|Placebo
NCT03976401,"Akero Therapeutics, Inc",28-MAY-19,10-JAN-22,Interventional,,A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH),"A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Nonalcoholic Steatohepatitis (NASH)",Completed,Phase 2,110,6,EFX|Placebo
NCT03978247,Diafir,21-JUN-19,31-OCT-20,Interventional,,Signature Diagnostic of Non-alcoholic Steatohepatitis (NASH) by Infrared Light Spectroscopy,Validation Study of the NASHMIR Test for Non-alcoholic Steatohepatitis (NASH) Diagnosis in Patients With Severe or Morbid Obesity,Completed,Not Applicable,382,1,NASHMIR
NCT03987451,Novo Nordisk A/S,18-JUN-19,10-JUN-21,Interventional,,A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage,Investigation of Efficacy and Safety of Semaglutide s.c. Once-weekly Versus Placebo in Subjects With Non-alcoholic Steatohepatitis and Compensated Liver Cirrhosis,Completed,Phase 2,71,2,Semaglutide|Placebo (semaglutide)
NCT04480710,"Hepion Pharmaceuticals, Inc.",23-JUN-20,30-OCT-21,Interventional,,A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects,"AMBITION: A Phase 2A, Multiple-Center, Single-Blind, Placebo-Controlled Study To Evaluate The Safety and Tolerability of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects",Completed,Phase 2,49,4,CRV431 75mg|Placebo (1 softgel)|CRV431 225mg|Placebo (3 softgels)
NCT03998514,"CohBar, Inc.",09-JUL-18,19-APR-21,Interventional,,A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease,"A Phase 1a/1b Study of Safety, Tolerability, and Pharmacokinetics of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease",Completed,Phase 1,88,10,CB4211 Dose 1|CB4211 Dose 2|CB4211 Dose 3|CB4211 Dose 4|CB4211 Dose 5|CB4211 Dose 6|CB4211 Dose TBD|Placebo
NCT04505436,Hanmi Pharmaceutical Company Limited,29-JUL-20,10-NOV-24,Interventional,,"Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects","A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects With Biopsy Confirmed NASH",Recruiting,Phase 2,217,2,HM15211|Placebo of HM15211
NCT04523584,Siemens Medical Solutions,15-AUG-20,14-FEB-22,Observational,,Ultrasound Quantification of Liver Fat,Ultrasound Quantification of Liver Fat,Recruiting,,56,,Magnetic Resonance Imaging (MRI)|Ultrasound Imaging
NCT04004325,"Forma Therapeutics, Inc.",17-MAY-19,20-JAN-20,Interventional,,A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis,"A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability and Efficacy of FT-4101 in Overweight/Obese Subjects With NASH",Terminated,Phase 1/Phase 2,14,2,FT-4101|FT-4101 placebo|Deuterated Water
NCT04006145,Albireo,06-JUN-19,15-JUL-20,Interventional,,A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH,"A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study to Explore the Efficacy and Safety of Elobixibat in Adults With Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)",Completed,Phase 2,47,2,Elobixibat|Placebo oral tablet
NCT04019561,MedImmune LLC,23-SEP-19,06-MAY-21,Interventional,,A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.,"A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacodynamic Effects of MEDI0382 in Obese Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)/ Non-Alcoholic Steatohepatitis (NASH)",Completed,Phase 2,74,4,MEDI0382 high dose|Placebo for MEDI0382 high dose|MEDI0382 low dose|Placebo for MEDI0382 low dose
NCT04054297,Unilever R&D,22-JUL-19,23-MAR-21,Interventional,,Glycemic Index/Saturated Fatty Acid Diet and Hepatic Fat,The Effect of a Low Compared to a High Glycemic Index/Saturated Fatty Acid Diet on Hepatic Fat,Completed,Not Applicable,13,2,High GI/SFA diet|Low GI/SFA diet
NCT04048876,Celgene,14-AUG-19,28-SEP-21,Interventional,,Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Finding Study To Evaluate The Efficacy and Safety Of CC-90001 In Subjects With Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis",Terminated,Phase 2,56,4,CC-90001|Placebo
NCT04054310,Perspectum,05-AUG-20,30-JUN-22,Interventional,,Non-Invasive Quantification of Liver Health in NASH (N-QUAN),Non-Invasive Quantification of Liver Health in NASH (N-QUAN): A Prospective Diagnostic Accuracy Study,Recruiting,Not Applicable,225,1,Liver Multi Scan
NCT04065841,Novartis Pharmaceuticals,11-DEC-19,29-MAR-24,Interventional,,"Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.","A Randomized, Double-blind, Parallel-group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Oral Tropifexor (LJN452) & Licogliflozin (LIK066) Combination Therapy and Each Monotherapy, Compared With Placebo for Treatment of Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis.(ELIVATE)",Recruiting,Phase 2,380,4,Tropifexor|Licogliflozin|Placebo
NCT04565717,Alnylam Pharmaceuticals,09-OCT-20,04-JAN-23,Interventional,,A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH),"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH)","Active, not recruiting",Phase 1,103,4,ALN-HSD|Placebo
NCT04583423,Merck Sharp & Dohme LLC,11-NOV-20,29-MAY-24,Interventional,,A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001),"A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis.",Recruiting,Phase 2,328,4,MK-3655|Placebo
NCT04140123,"Guangdong Raynovent Biotech Co., Ltd",23-JUN-20,03-AUG-21,Interventional,,"Tolerability, Efficacy, and PK of ZSP1601 in Patients With Non-Alcoholic Steatohepatitis (NASH)","A Multi-center, Randomized, Double-blind, Dose-increasing, Placebo-controlled，Multi-dose, 28-day Continuous Administration Phase Ib/IIa Clinical Trial to Evaluate the Tolerability, Efficacy, and PK of ZSP1601 in Patients With Nonalcoholic Steatohepatitis",Completed,Phase 1/Phase 2,37,4,ZSP1601|ZSP1601 Placebo
NCT04639414,Novo Nordisk A/S|Boehringer Ingelheim,26-MAR-21,31-DEC-23,Interventional,,Combined Active Treatment in Type 2 Diabetes With NASH,Combined Active Treatment in Type 2 Diabetes With NASH,Recruiting,Phase 4,192,3,Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector|Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide|Placebo matching empagliflozin and placebo pen injector matching semaglutide
NCT04685993,Lipocine Inc.,11-NOV-20,31-AUG-22,Interventional,,A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial,An Open Label Extension Study of the Safety and Tolerability of LPCN 1144 for the Treatment of Subjects With Nonalcoholic Steatohepatitis (NASH) Who Have Completed the LPCN 1144-18-002 Trial,"Active, not recruiting",Phase 2,20,1,LPCN 1144
NCT04697810,Can-Fite BioPharma,10-DEC-21,15-APR-23,Interventional,,Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH),"A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)",Recruiting,Phase 2,114,2,Namodenoson|Placebo
NCT04702490,"Metacrine, Inc.",15-DEC-20,30-JUN-22,Interventional,,Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH,A Phase 2A Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes Mellitus (T2DM) and Nonalcoholic Steatohepatitis (NASH),"Active, not recruiting",Phase 2,120,4,MET409 Active|MET409 Placebo|Empagliflozin
NCT04722653,Novo Nordisk A/S,02-FEB-21,27-APR-21,Interventional,,A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian Men,"Investigation of Safety, Tolerability and Pharmacokinetic Properties of Single Subcutaneous Doses of NNC0194-0499 in Japanese and Non-Asian Male Subjects",Completed,Phase 1,42,2,NNC0194-0499|Placebo (NNC0194-0499 )
NCT04771273,Boehringer Ingelheim,27-APR-21,08-MAR-24,Interventional,,A Study to Test Safety and Efficacy of BI456906 in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3),"Multicenter, Double-blind, Parallel-group, Randomized, 48 Weeks, Dose-ranging, Placebo-controlled Phase II Trial to Evaluate Efficacy, Safety and Tolerability of Multiple Subcutaneous (s.c.) Doses of BI 456906 in Patients With Non-alcoholic Steatohepatitis (NASH) and Fibrosis.",Recruiting,Phase 2,240,4,BI 456906|Placebo
NCT04773964,"Metacrine, Inc.",03-MAR-21,14-FEB-22,Interventional,,Study to Evaluate MET642 in Patients With NASH,"Phase 2a Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MET642 in Patients With Nonalcoholic Steatohepatitis (NASH)","Active, not recruiting",Phase 2,215,3,MET642|Placebo
NCT04073368,"Axcella Health, Inc",03-DEC-18,03-SEP-20,Interventional,This is the safety analysis population,Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD),"A 16-Week, Single-Blind Randomized, Placebo- Controlled Food Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)",Completed,Not Applicable,112,4,AXA1957|AXA1125|Placebo
NCT04109742,Thorne Research Inc.,09-DEC-19,22-APR-20,Interventional,,Curcumin for Pediatric Nonalcoholic Fatty Liver Disease,Curcumin for Pediatric Nonalcoholic Fatty Liver Disease: A Pilot Randomized Controlled Trial,Withdrawn,Phase 2,0,3,phosphatidylcholine-curcumin complex supplement|Placebo curcumin capsule
NCT04134091,Lipocine Inc.,27-AUG-19,24-JUN-21,Interventional,,"A Study to Assess the Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis (NASH)","A Phase 2, Randomized Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis (NASH)",Completed,Phase 2,56,3,LPCN 1144 Formulation A|LPCN 1144 Formulation B|Placebo
NCT04142424,Parexel|AstraZeneca,28-OCT-19,12-NOV-21,Interventional,,"A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects","A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2693 Following Single Ascending Dose Administration in Male and Female Subjects of Non-childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects",Completed,Phase 1,73,9,AZD2693|Placebo
NCT04142749,PharmaKing,15-NOV-19,31-OCT-21,Interventional,,Oltipraz for Liver Fat Reduction in Patients With Non-alcoholic Fatty Liver Disease Except for Liver Cirrhosis,"A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Oltipraz",Recruiting,Phase 3,144,2,Oltipraz|Placebos
NCT04147195,Novartis Pharmaceuticals,04-JUN-20,06-JAN-22,Interventional,,Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH),"NASH EXploratory Single and COmbination Treatment (NEXSCOT): An Open Label, Multicenter, Platform Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Various Single and Combination Treatments in Patients With Non-alcoholic Fatty Liver Disease (NAFLD) Who Manifest a Non-alcoholic Steatohepatitis (NASH)-Like Biomarker Phenotype",Terminated,Phase 2,41,2,LYS006|LYS006 + Tropifexor (LJN452)
NCT04146805,Blade Therapeutics,10-JAN-20,12-APR-21,Interventional,,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BLD-0409 in Healthy Subjects","A Phase 1a, Double Blind, Placebo-Controlled, Single-Center, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of BLD-0409 in Healthy Volunteers",Completed,Phase 1,80,2,BLD-0409|Control: Placebo
NCT04782050,E-Scopics,15-SEP-21,15-SEP-22,Interventional,,Non-invasive Ultrasound Diagnosis of Chronic Liver Diseases in Hepatology Consultation,Diagnostic échographique Non-invasif Des Maladies Chroniques du Foie en Consultation d'hépatologie,Recruiting,Not Applicable,100,1,Ultrasound liver assessment
NCT04187339,"NGM Biopharmaceuticals, Inc",13-FEB-20,22-APR-21,Interventional,,Study of NGM395 in Adult Participants,"A Phase 1, Randomized, Placebo-controlled, Double-blind, Two-part Study to Evaluate the Safety and Tolerability of NGM395 in Adult Obese Patients (Part 1) and in Adult Patients With Nonalcoholic Fatty Liver Disease (NAFLD) (Part 2).",Completed,Phase 1,38,7,NGM395|NGM395|NGM395|NGM395|NGM395|NGM395|Placebo
NCT04800094,Philips Clinical & Medical Affairs Global,02-MAR-21,30-AUG-22,Interventional,,Pediatric Liver Fat Quantification (LFQ) Phase 2 Pilot Study,Pilot Study of On-Cart Liver Fat Quantification (LFQ) Feature to Assess Correlation With Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) Results in a Pediatric Population,Recruiting,Not Applicable,30,1,Investigational Liver Fat Quantification Software
NCT04808154,Sinew Pharma Inc.,22-JUL-21,31-AUG-21,Interventional,,"A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of SNP-630 in Health Subjects.","A Phase I Single Dose Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of SNP-630 in Health Subjects.",Completed,Phase 1,28,1,SNP-630
NCT04820036,Boston Scientific Corporation,06-MAY-21,31-DEC-22,Interventional,,A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG),A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG): Effects of ESG on Non-Alcoholic Steatohepatitis (NASH) and Portal Pressure Gradient in Patients With Obesity and NASH With Advanced Fibrosis,Recruiting,Not Applicable,12,1,Insulin Resistance|Quality of Life Assessment|Liver Function Test|Radiologic features of NASH|Serologic features of NASH
NCT04829123,"Dongguan HEC Biopharmaceutical R&D Co., Ltd.",29-MAY-21,31-DEC-22,Interventional,,"The Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of HEC88473 in Healthy Subjects","A Phase 1, Double Blind, Placebo Controlled, Single and Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of HEC88473 in Healthy Subjects",Recruiting,Phase 1,100,11,HEC88473 injection|Placebo
NCT04166773,Eli Lilly and Company,19-NOV-19,15-DEC-23,Interventional,,A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH),"A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)",Recruiting,Phase 2,196,4,Tirzepatide|Placebo
NCT04194242,"Sunshine Lake Pharma Co., Ltd.",03-JAN-20,17-JUL-20,Interventional,,"The Tolerability , Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Adult Subjects","A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Access the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HEC96719 Tablets in Chinese Healthy Volunteers",Completed,Phase 1,64,2,HEC96719 tablets|Placebo tablet
NCT04197479,"Madrigal Pharmaceuticals, Inc.",16-DEC-19,31-DEC-21,Interventional,,A Phase 3 Study to Evaluate the Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease (NAFLD) Patients,"A 52-Week, Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD) (MAESTRO-NAFLD-1)",Recruiting,Phase 3,700,4,Placebo|Resmetirom
NCT04202354,Arrowhead Pharmaceuticals,03-MAR-20,23-NOV-21,Interventional,,Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASH,"A Phase 1/2a Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-HSD in Normal Healthy Volunteers as Well as in Patients With NASH or Suspected NASH",Completed,Phase 1,50,2,ARO-HSD Injection|sterile normal saline (0.9% NaCl)
NCT04845646,"Gannex Pharma Co., Ltd.",16-MAR-21,10-JUN-21,Interventional,,"DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.","Phase I Open Label, Drug-Drug Interaction, Study to Evaluate the Effect of Itraconazole and Phenytoin on the Pharmacokinetics of ASC41 in Healthy Volunteers and A Study to Evaluate the PK, Safety and Tolerability in Subjects With Non-alcoholic Fatty Liver Disease (NAFLD).",Completed,Phase 1,24,3,ASC41|Itraconazole|Phenytoin
NCT04198805,"DSM Nutritional Products, Inc.",03-JAN-20,01-DEC-22,Interventional,,"Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)","The Effect of Vitamin E and Docosahexaenoic Acid Ethyl Ester on Non-Alcoholic Fatty Liver Disease (NAFLD) - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)",Recruiting,Phase 2,200,4,Vitamin E [(all-rac)-α-tocopheryl acetate]|Omega-3 fatty acid (DHA EE)|Omega-3 fatty acid (DHA EE) & Vitamin E [(all-rac)-α-tocopheryl acetate]|Placebo
NCT04235205,"EA Pharma Co., Ltd.",29-JAN-20,30-SEP-21,Interventional,,Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease,"Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Patients With Nonalcoholic Fatty Liver Disease: a Single Center, Double-blind, Randomized, Placebo-Controlled, Phase 2a Trial.",Completed,Phase 2,102,4,Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g)|Elobixibat 10mg + cholestyramine powder placebo|Elobixibat placebo + cholestyramine powder 9g (cholestyramine 4g)|Elobixibat placebo + cholestyramine powder placebo
NCT04857606,Amgen,24-MAY-21,07-MAY-23,Interventional,,Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease,"A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 609 in Subjects With Non-alcoholic Fatty Liver Disease",Recruiting,Phase 1,106,2,AMG 609|Placebo
NCT04210245,"NGM Biopharmaceuticals, Inc",23-MAR-20,31-MAR-23,Interventional,,Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4),"Evaluation of Efficacy, Safety and Tolerability of NGM282 (Aldafermin) in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (ALPINE 4)","Active, not recruiting",Phase 2,160,4,aldafermin|Placebo
NCT04237116,Novartis Pharmaceuticals,19-FEB-20,23-JUL-21,Interventional,,A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD),"A Randomized, Double-blind, Multicenter, 24-week Study of Subcutaneous Secukinumab to Assess Anti-interleukin-17A Treatment in Plaque Psoriasis Patients With Coexisting Non-alcoholic Fatty Liver Disease (pINPOINt)",Completed,Phase 3,10,2,Investigational Arm - secukinumab|Control Arm - placebo
NCT04321031,Pfizer,15-JUN-20,26-DEC-23,Interventional,,Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA),"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, DOSE-RANGING, DOSE-FINDING, PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF-06865571 (DGAT2I) ALONE AND WHEN COADMINISTERED WITH PF-05221304 (ACCI) IN ADULT PARTICIPANTS WITH BIOPSY-CONFIRMED NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS STAGE 2 OR 3",Recruiting,Phase 2,350,7,Placebo|PF-06865571|PF-05221304
NCT04255069,"TaiwanJ Pharmaceuticals Co., Ltd",30-JUN-20,31-DEC-23,Interventional,,A Study to Evaluate the Efficacy and Safety of JKB-122 in Patients With NASH and Fibrosis,"A Phase 2, Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled Study of JKB-122 in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis",Not yet recruiting,Phase 2,300,3,Placebo|Dose 1 JKB-122|Dose 2 JKB-122
NCT04321343,Poxel SA,01-SEP-20,30-JUN-22,Interventional,,Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH),"A 36-week, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Assess the Efficacy and Safety of PXL065 Versus Placebo in Noncirrhotic Biopsy-proven NonAlcoholic SteatoHepatitis (NASH) Patients","Active, not recruiting",Phase 2,123,4,PXL065|Placebo oral tablet
NCT04897594,"Terns, Inc.",20-MAY-21,31-OCT-22,Interventional,,"AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis","A Multi-Center, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled, Proof of Concept, Adaptive, Phase 1b Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Orally Administered TERN-201 in Patients With Presumed Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)","Active, not recruiting",Phase 1,60,4,TERN-201|Placebo
NCT04906421,Sagimet Biosciences Inc.,12-AUG-21,28-OCT-23,Interventional,,Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH),"A Phase 2B, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (FASCINATE-2)",Recruiting,Phase 2,162,2,TVB-2640|Placebo
NCT04913090,"Xuanzhu Biopharmaceutical Co., Ltd.",31-MAY-21,04-MAR-22,Interventional,,A Phase I Clinical Trial of XZP-5610 Tablets in Healthy Subjects,"A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) of XZP-5610 Tablets Following Single- and Multiple-ascending Doses (SAD/MAD) and Food Effects in Healthy Subjects.",Recruiting,Phase 1,112,6,"XZP-5610 Tablet (for Part A)|Placebo to match XZP-5610 Tablet (for Part A)|XZP-5610 Tablet (for Part B)|Placebo to match XZP-5610 Tablet (for Part B)|XZP-5610 Tablet （for ""Part C1""）|XZP-5610 Tablet for ""Part C2"""
NCT04929483,"89bio, Inc.",04-JUN-21,30-SEP-23,Interventional,,"Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)","A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of BIO89-100 in Subjects With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)",Recruiting,Phase 2,216,5,BIO89-100
NCT04951219,"Madrigal Pharmaceuticals, Inc.",09-JUL-21,31-DEC-22,Interventional,,"A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)","A 52-Week, Phase 3, Open-Label Extension Study, With a Single-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)",Recruiting,Phase 3,1000,3,Resmetirom
NCT04972396,"Altimmune, Inc.",05-OCT-21,28-FEB-22,Interventional,,ALT-801 DDI Study in Healthy Volunteers,"An Open-label Study of the Effect of ALT-801 on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin, Digoxin, and the Combined Oral Contraceptive Ethinylestradiol/Levonorgestrel in Healthy Volunteers",Recruiting,Phase 1,36,3,ALT-801|Metformin|Atorvastatin|Warfarin|Digoxin|Ethinylestradiol and Levonorgestrel
NCT04328077,"Terns, Inc.",18-JUN-20,03-MAY-21,Interventional,,"LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2a Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Orally Administered TERN-101 Tablets in Adult Patients With Presumed Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)",Completed,Phase 2,101,4,TERN-101|Placebo
NCT04336800,Perspectum,01-APR-20,01-JAN-22,Observational,,Multi-Parametric MRI Assessment of the Liver in Diabetic Volunteers (Partners Registry),Multi-Parametric MRI Assessment of the Liver in Diabetic Volunteers (Partners Registry),Recruiting,,200,,LiverMultiscan
NCT04330326,Monitor CRO|ScandiBio Therapeutics AB,20-JUL-19,30-SEP-20,Interventional,,Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease,"A Phase 2, Randomised, Placebo Controlled Study to Evaluate the Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation in Obese Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)",Unknown status,Phase 2,45,2,Metabolic Cofactor Supplementation|Sorbitol
NCT04336618,Perspectum,03-AUG-20,31-DEC-22,Observational,,Multi-Parametric MRI Assessment of the Liver in the Dallas-FortWorth Metroplex Population,Multi-Parametric MRI Assessment of the Liver in the Dallas-FortWorth Metroplex Population,Recruiting,,100,,Liver MultiScan
NCT04342793,"AngioLab, Inc.",04-DEC-19,30-SEP-21,Interventional,,A Study to Evaluate the Efficacy and Safety of ALS-L1023 in Subjects With NASH,"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2a Study to Explore the Safety and Efficacy of ALS-L1023 in Patients With Non-alcoholic Steatohepatitis (NASH)",Unknown status,Phase 2,60,3,"Placebo oral tablet|ALS-L1023 1,200mg|ALS-L1023 1,800mg"
NCT04365868,Galectin Therapeutics Inc.,22-JUN-20,31-DEC-23,Interventional,,Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis,"A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis",Recruiting,Phase 2/Phase 3,1010,3,belapectin|Placebo
NCT05006885,"Altimmune, Inc.",30-SEP-21,28-FEB-22,Interventional,,ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD),"A Phase 1, 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease",Recruiting,Phase 1,72,4,ALT-801|Placebo
NCT05012423,Eccanga Pty Ltd,07-JUL-21,20-FEB-22,Interventional,,FTIH Study of ECC0509 in Healthy Volunteers,"A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single And Multiple Ascending Dose, First-Time-In-Human Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Ecc0509 In Healthy Volunteers",Recruiting,Phase 1,86,4,Placebo|ECC0509|Placebo|ECC0509
NCT04463017,"Rivus Pharmaceuticals, Inc.",12-AUG-20,01-APR-21,Interventional,,Ascending Dose Study of HU6 in Healthy Volunteers,"A Double-blind, Placebo-controlled, Phase I Study of the Safety and Pharmacokinetics of Single Ascending Doses of HU6 in Healthy Volunteers",Completed,Phase 1,64,2,HU6
NCT05016882,Novo Nordisk A/S,31-AUG-21,20-SEP-24,Interventional,,Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH),"Efficacy and Safety Investigation of NNC0194-0499 Co-administered With Semaglutide in Subjects With Non-alcoholic Steatohepatitis: a Dose-ranging, Placebo Controlled Trial",Recruiting,Phase 2,672,10,NNC0194 0499 50 mg/mL|Placebo (NNC0194-0499)|Semaglutide 3 mg/mL|Semaglutide placebo|NNC0174 0833 10 mg/mL|NNC0174 0833 placebo
NCT05041673,Eva Pharma,23-FEB-21,30-SEP-22,Interventional,,Anti-diabetic Drugs and Fatty Liver Management,"Efficacy of Vildagliptin, Liraglutide and Empagliflozin in the Management of Fatty Liver Disease Among Patients With Type 2 Diabetes","Active, not recruiting",Not Applicable,120,4,Metformin
NCT05083390,Dr. Falk Pharma GmbH,08-JUL-19,30-APR-22,Interventional,,Norursodeoxycholic Acid vs. Placebo in NASH,"Double-blind, Randomised, Placebo-controlled, Phase IIb Trial on the Efficacy and Safety of Norursodeoxycholic Acid Tablets in Patients With Non-alcoholic Steatohepatitis (NASH)",Recruiting,Phase 2,363,3,norUrsodeoxycholic acid
NCT04395950,Pfizer,31-DEC-20,19-AUG-21,Interventional,,Effects of ACC Inhibitor on Lipid and Lipoprotein Metabolism,"A Phase 1B, Single-Blinded, Linear Two Period, Placebo-controlled Study to Evaluate the Effects of 10 mg/Day of PF-05221304, Liver Targeted Acetyl-CoA Carboxylase Inhibitor (ACCi) on Very Low Density Lipoprotein ApoB100 and TG Secretion",Withdrawn,Phase 1,0,2,PF-05221304|Placebo
NCT04546984,"Sunshine Lake Pharma Co., Ltd.",14-SEP-20,29-DEC-20,Interventional,,"Multiple Dose Safety, Tolerability, PK，PD and Food Effect Study of HEC96719 in Healthy Adult Subjects","A Randomized, Double-Blind, Placebo-Controlled Study of Ascending Multiple Doses to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics，and Randomized, Open-label，Crossover, Food Effect Study of HEC96719 in Healthy Chinese Subjects",Completed,Phase 1,66,6,HEC96719
NCT04481594,Hepanova Inc.,08-SEP-20,31-JUL-21,Interventional,,A Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of HPN-01 in Healthy Subjects,"A Randomized, Double-Blind, Placebo Controlled, Sequential Parallel Group, Single and Multiple Ascending Doses (SAD/MAD) Study Following Oral Administration in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HPN-01",Recruiting,Phase 1,72,2,HPN-01|Placebo
NCT04483947,AstraZeneca|Parexel,06-NOV-20,24-NOV-22,Interventional,,"A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients","A Phase 1, Double Blind, Randomised, Placebo-Controlled, Multi-centre, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2693 in Patients With Non-alcoholic Steatohepatitis (NASH) With Fibrosis Stage 0-3 and Carriers of the PNPLA3 148M Risk Alleles",Recruiting,Phase 1,60,3,AZD2693|Placebo
NCT04521114,"CytoDyn, Inc.",01-DEC-20,22-JUL-22,Interventional,,Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis(NASH),"A Phase II, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Two-Arm Study of the Safety and Efficacy of Leronlimab (PRO 140) in Adult Patients With Nonalcoholic Steatohepatitis (NASH)","Active, not recruiting",Phase 2,60,2,Placebos|leronlimab
NCT04561245,"Altimmune, Inc.",10-NOV-20,23-OCT-21,Interventional,,ALT-801 in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability,"A Randomized, Double-Blind, Placebo-Controlled Study of Single and Multiple Ascending Doses of ALT-801 in Healthy Overweight and Obese Volunteers",Completed,Phase 1,100,4,ALT-801|Placebo
NCT05117489,Corcept Therapeutics,23-NOV-21,30-NOV-22,Interventional,,"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)","A Phase 1b, Open-Label Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Adult Patients With Presumed Nonalcoholic Steatohepatitis (NASH)",Recruiting,Phase 1,36,6,Miricorilant 150 mg|Miricorilant 100 mg
NCT05118360,"Gannex Pharma Co., Ltd.",30-MAR-22,09-JAN-24,Interventional,,"Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH","A Seamless Phase 2a/2b, Double-Blind, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41, a Thyroid Hormone Receptor β Agonist, in Adults With Nonalcoholic Steatohepatitis (NASH)",Not yet recruiting,Phase 2,180,4,ASC41 2 mg|ASC41 4 mg|Placebo
NCT04559126,Enanta Pharmaceuticals|PRA Health Sciences,08-SEP-20,21-JUN-21,Interventional,,A Study of EDP-297 in Healthy Subjects,"A Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study of Orally Administered EDP-297 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (SAD), Multiple Ascending Doses (MAD), and the Effect of Food on EDP-297 Pharmacokinetics in Healthy Subjects",Completed,Phase 1,82,4,EDP-297|Placebo
NCT04643795,"Madrigal Pharmaceuticals, Inc.",24-OCT-18,31-MAR-21,Interventional,,"Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects","A Phase I, Open Label, Non-randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects With Normal Hepatic Function",Recruiting,Phase 1,90,4,MGL-3196
NCT04576923,Sonic Incytes,01-FEB-21,31-DEC-25,Interventional,,Quantitative Ultrasound With Liver Incytes for Evaluation of Non-Alcoholic Fatty Liver Disease,Quantitative Ultrasound With Liver Incytes for Evaluation of Non-Alcoholic Fatty Liver Disease,Recruiting,Not Applicable,100,1,Liver Incytes
NCT04607655,Galecto Biotech AB|Covance,31-MAR-21,31-JUL-22,Interventional,,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis","GULLIVER-1 - A Randomised, Double-Blind, Placebo Controlled, Phase Ib, 12-week Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis",Withdrawn,Phase 1/Phase 2,0,3,GB1211|Placebo
NCT04616014,"Oramed, Ltd.",01-MAR-21,30-JUN-22,Interventional,,A Study of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH),An Open-Label Multi-Center Study to Assess the Safety and Potential of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH),Recruiting,Phase 2,40,2,ORMD-0801 QD|ORMD-0801 BD
NCT04618744,"Oramed, Ltd.|Integrium",24-NOV-20,30-JUN-22,Interventional,,A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH),"A Double-Blind, Randomized, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH)",Recruiting,Phase 2,36,2,ORMD-0801 (Insulin) capsule 8 mg BD|Placebo
NCT04657523,Philips Clinical & Medical Affairs Global,30-OCT-20,15-DEC-22,Interventional,,Ultrasound-Based Liver Fat Quantification (LFQ) Pilot Study,Pilot Study of On-Cart Liver Fat Quantification (LFQ) Feature to Assess Correlation With Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) Results,Recruiting,Not Applicable,60,1,Investigational Liver Fat Quantification Software
NCT04709913,"Rivus Pharmaceuticals, Inc.",04-JAN-21,30-JUL-21,Interventional,,Multiple Ascending Dose Study of HU6 in High BMI Volunteers,"A Double-blind, Sponsor-Open, Placebo-controlled, Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of HU6 in High BMI Volunteers",Completed,Phase 1,30,2,HU6
NCT04682600,Sonic Incytes,21-OCT-20,31-MAY-22,Interventional,,"The Sonic Incytes Liver Incytes System, Evaluation of Liver Fibrosis and Steatosis Versus MRE and MRI PDFF","The Sonic Incytes Liver Incytes System, Evaluation of Liver Fibrosis and Steatosis Versus MRE and MRI PDFF",Recruiting,Not Applicable,100,1,Liver Incytes System
NCT04704063,Hovid Berhad,01-JAN-21,01-JUN-23,Interventional,,Efficacy and Safety of Tocovid Suprabio 200mg in Non-alcoholic Fatty Liver (NAFL),"A Randomized, Double-Blind, Placebo-Controlled Study, to Assess the Efficacy and Safety of Tocovid Suprabio 200mg in Non-alcoholic Fatty Liver (NAFL)",Recruiting,Phase 2,170,2,Tocotrienols / Vitamin E|Placebo control
NCT04710524,Future Medicine,10-JUN-21,03-JUL-22,Interventional,,FM101 Efficacy Study in Adults With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis,"A Randomized Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of FM101 in Adults With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis",Recruiting,Phase 2,60,3,Placebo|FM101 150 mg BID|FM101 300 mg BID
NCT05305599,Dr. Falk Pharma GmbH,30-APR-22,30-JUN-22,Interventional,,Different Doses of ZED1227 vs. Placebo in NAFLD,"Double-blind, Randomized, Placebo-controlled, Phase II Dose-finding Study Comparing Different Doses of ZED1227 Capsules With Placebo in the Treatment of Non-alcoholic Fatty Liver Disease (NAFLD) With Significant Fibrosis",Not yet recruiting,Phase 2,160,4,ZED1227|Placebo
NCT05338034,"Hepagene (Shanghai) Co., Ltd.",22-NOV-21,31-MAR-23,Interventional,,Phase 2a Study of HPG1860 in Subjects With NASH,"A Randomized, Double-blind, Placebo-controlled Parallel Group Phase 2a Study to Evaluate the Efficacy and Safety of HPG1860 in Subjects With Nonalcoholic Steatohepatitis",Recruiting,Phase 2,80,4,HPG1860|Placebo
NCT05343780,Natural Wellness Egypt,08-MAY-19,21-FEB-22,Interventional,,Clinical Trial to Investigate the Anti-oxidant Activity of Heptex in Patients With Apparent Risk Factors of NASH,"A Phase II, Randomized, Double Blind, Placebo-Controlled Clinical Trial to Investigate the Anti-oxidant Activity of Heptex in Patients With Apparent Risk Factors of Nonalcoholic Steatohepatitis (NASH)",Completed,Phase 2,142,3,Heptex|Rice bran
NCT04812262,"Neuraly, Inc.",24-FEB-21,31-DEC-22,Interventional,,A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD,"A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DD01 in Overweight/Obese Subjects With T2DM and NAFLD",Recruiting,Phase 1,120,15,DD01|Placebo
NCT04766476,Bristol-Myers Squibb,24-FEB-21,12-AUG-21,Interventional,,"A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease",Terminated,Phase 1,9,3,BMS-963272|Placebo matching BMS-963272
NCT04767529,"Akero Therapeutics, Inc",16-FEB-21,31-MAY-24,Interventional,,A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH),"A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH)","Active, not recruiting",Phase 2,128,3,EFX|Placebo
NCT04781933,Mativa-Tech SA,01-OCT-21,01-MAY-22,Interventional,,"Interest in ""Combo"" (a Combination of Dietary Supplements Including Probiotics) in NASH Improvement","Interest in ""Combo"" (a Combination of Dietary Supplements Including Probiotics) in NASH Improvement",Not yet recruiting,Not Applicable,60,2,Treatment with Combo|Treatment with placebo
NCT04807868,"Berg, LLC",22-APR-21,31-MAR-26,Observational [Patient Registry],,AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL),AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL),Recruiting,,1250,,Standard of care liver biopsy|Fibroscan|Biospecimen Collection
NCT04823676,"AB Biotics, SA",31-MAR-21,22-FEB-22,Interventional,,Efficacy and Safety of a Probiotic Composition as Adjunct in MAFL Management,Efficacy and Safety of a Probiotic Composition as Adjunct Treatment in the Comprehensive Management of Metabolism-Associated Hepatic Steatosis in Adults,Completed,Not Applicable,100,2,Probiotic composition|Placebo
NCT04822181,Novo Nordisk A/S,01-APR-21,26-MAY-28,Interventional,,Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH),The Effect of Semaglutide in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis,Recruiting,Phase 3,1200,2,Semaglutide|Placebo
NCT04841915,Arla Foods,15-MAR-21,31-JUL-23,Interventional,,A Randomized Controlled Trial of Effects of DAIry PROtein Products on Liver Disease Severity and Metabolism in Patients With Non-Alcoholic Fatty Liver Disease.,A Randomized Controlled Trial of Effects of DAIry PROtein Products on Liver Disease Severity and Metabolism in Patients With Non-Alcoholic Fatty Liver Disease.,Recruiting,Not Applicable,54,3,High-Protein Diet|Clinical dietician|Weight loss
NCT04849728,Inventiva Pharma,19-AUG-21,30-SEP-28,Interventional,,A Phase 3 Study Evaluating Long-term Efficacy and Safety of Lanifibranor in Adult Patients With (NASH) and Fibrosis 2 (F2)/Fibrosis 3 (F3) Stage of Liver Fibrosis,"A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Study Evaluating Long-term Efficacy and Safety of Lanifibranor in Adult Patients With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) and Fibrosis 2 (F2)/Fibrosis 3 (F3) Stage of Liver Fibrosis",Recruiting,Phase 3,2000,3,IVA337|Placebo
NCT04857437,Pfizer,13-MAY-21,17-SEP-21,Interventional,,Study in Healthy Adults Evaluating PF-07202954,"A PHASE 1, 3-PART, SPONSOR OPEN STUDY OF PF-07202954 IN HEALTHY ADULTS: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TO ASSESS SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE (IN PART 1), AND REPEATED (IN PART 2), ESCALATING, ORAL DOSES ALONG WITH CONDITIONAL PART 3 OF RANDOMIZED, OPEN-LABEL ASSESSMENT OF EFFECT OF FOOD ON PF-07202954 EXPOSURE",Completed,Phase 1,12,3,PF-07202954 Repeat Dose|PF-07202954 Single Dose|Placebo
NCT04872777,Noom Inc.,08-JUN-21,10-FEB-22,Interventional,,Mobile Health Delivered Lifestyle Intervention Program in Patients With NASH,Mobile Health Delivered Lifestyle Intervention Program in Patients With Nonalcoholic Steatohepatitis: A Proof of Concept Study,Completed,Not Applicable,40,2,Noom Healthy Weight
NCT04874233,"Rivus Pharmaceuticals, Inc.",19-APR-21,15-DEC-21,Interventional,,Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers,"A 61-day Randomized, Double Blind, Placebo-controlled Trial to Assess the Safety and Efficacy of Three Doses of HU6 in Subjects With Elevated Liver Fat and High Body Mass Index (28 to 45 kg/m2)",Completed,Phase 2,80,4,HU6|Placebo
NCT04887766,"Gelesis, Inc.",01-JUL-22,31-DEC-23,Interventional,,Study on GS300 on NAFLD,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of GS300 on Nonalcoholic Fatty Liver Disease",Not yet recruiting,Not Applicable,250,2,GS300|Placebo
NCT04880031,Boston Pharmaceuticals,30-SEP-21,31-AUG-23,Interventional,,A Study of BOS-580 in Obese Subjects at Risk for Nonalcoholic Steatohepatitis (NASH),"A 12-week Phase 2a Randomized, Blinded, Placebo Controlled Study of BOS-580 in Obese Subjects at Risk for Nonalcoholic Steatohepatitis (NASH)",Recruiting,Phase 2,75,5,BOS-580|Placebo
NCT04880187,"Axcella Health, Inc",07-MAY-21,31-OCT-23,Interventional,,"Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis","A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of AXA1125 in Subjects With Non Cirrhotic, Non Alcoholic Steatohepatitis and Fibrosis (EMMPACT)",Recruiting,Phase 2,273,3,AXA1125|Placebo
NCT04931147,Redx Pharma Plc|Simbec Research,13-MAY-21,31-DEC-21,Interventional,,"A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers","A Randomised, Double-blind, Placebo-controlled, SAD/MAD First-in-human, Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RXC007 Including Evaluation of Drug-Drug Interaction and Food Effect in Male Participants",Recruiting,Phase 1,80,12,RXC007|RXC007 Matching Placebo
NCT04932512,"Ionis Pharmaceuticals, Inc.",18-JUN-21,31-MAR-24,Interventional,,"A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224","An Adaptive Two-Part Phase 2, Multi-Center, Randomized, Double Blind, Placebo-Controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224 Administered Once Monthly in Adult Subjects With Confirmed Non-Alcoholic Steatohepatitis",Recruiting,Phase 2,150,2,ION224|Placebo
NCT04938843,MetaboGen AB,16-AUG-21,31-DEC-23,Interventional,,Effect of F. Prausnitzii on Glycemic Control,"Effect of F. Prausnitzii on Glycemic Control - a Randomized, Double Blind, Placebo-controlled Study",Recruiting,Not Applicable,176,2,F. prausnitzii and D. piger|Placebo
NCT04944992,Merck Sharp & Dohme LLC,04-AUG-21,20-OCT-22,Interventional,,A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001),"A Phase 2a, Randomized, Active-Comparator-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Individuals With Nonalcoholic Fatty Liver Disease","Active, not recruiting",Phase 2,130,2,Efinopegdutide 20 mg/mL|Semaglutide 1.34 mg/mL
NCT04976283,Getz Pharma,15-SEP-21,15-NOV-23,Interventional,,Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver,Which Oral Combination of Anti-diabetes Medication May Work Better in Subjects With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: a Randomized Control Trial,Recruiting,Phase 4,123,3,Pioglitazone|Empagliflozin|Pioglitazone + Empagliflozin
NCT04971785,Gilead Sciences|Novo Nordisk A/S,09-AUG-21,31-MAR-24,Interventional,,"Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Participants With Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)","A Phase 2, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Subjects With Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)",Recruiting,Phase 2,440,4,Semaglutide (SEMA)|Cilofexor (CILO)/Firsocostat (FIR)|PTM SEMA|PTM CILO/FIR
NCT05022693,"89bio, Inc.",16-AUG-21,21-DEC-21,Interventional,,PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis,"An Open-Label, Single-Dose Pharmacokinetic Study of Liquid Subcutaneous Formulation of BIO89-100 in Subjects With Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis",Completed,Phase 1,8,1,BIO89-100
NCT05011305,Zydus Therapeutics Inc.,18-AUG-21,31-DEC-23,Interventional,,Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis,"A Phase 2b, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Saroglitazar Magnesium in Subjects With Nonalcoholic Steatohepatitis and Fibrosis",Recruiting,Phase 2,240,3,Saroglitazar Magnesium 2 mg|Saroglitazar Magnesium 4 mg|Placebo
NCT05037890,BASF|Unilever R&D|Raisio Group,20-FEB-20,31-DEC-23,Interventional,,Effects of Plant Sterols and Stanols on Liver Inflammation,The Effects of Plant Sterol and Plant Stanol Ester Enriched Foods on Liver Inflammation in Subjects at Risk to Develop NASH,Recruiting,Not Applicable,8,3,Margarine
NCT05051527,Mylan Inc.,01-MAY-22,31-JUL-23,Observational,,Study to Evaluate the Effectiveness of Legalon®,"Observational, Single Arm, Prospective Study to Evaluate the Effectiveness of Legalon® in Addition to Diet and Exercise in Reducing Plasma Levels of Liver Enzymes",Not yet recruiting,,362,,Legalon® 140 mg
NCT05039450,"Akero Therapeutics, Inc",30-JUL-21,30-APR-24,Interventional,,A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry),"A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)",Recruiting,Phase 2,200,3,EFX|Placebo
NCT05053165,Novotech (Australia) Pty Limited|LISCure Biosciences,12-NOV-21,01-JUN-22,Interventional,,A Study to Assess the Safety and Tolerability of LB-P6 and LB-P8 in Healthy Participants,"A Phase 1, Randomised, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of LB-P6 or LB-P8 in Healthy Participants",Recruiting,Phase 1,30,3,LB-P6|LB-P8|Placebo
NCT05063968,"Xuanzhu Biopharmaceutical Co., Ltd.",30-NOV-21,30-SEP-22,Interventional,,A Clinical Trial of XZP-6019 Tablets in Healthy Subjects,A Phase I Clinical Trial to Evaluate the Safety Tolerability Pharmacokinetics (PK) of XZP-6019 Tablets Following Single- and Multiple-ascending Doses (SAD/MAD) and Food Effects in Healthy Subjects,Not yet recruiting,Phase 1,120,6,XZP-6019 tablet|Placebo|XZP-6019 tablet|XZP-6019 tablet|XZP-6019 tablet|Placebo
NCT05120557,E-Scopics,30-JUN-22,30-JUN-23,Interventional,,Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH,Evaluation of Diagnostic Performances of a New Point-of-care Ultrasound System for the Detection of Fibrotic NASH and the Assessment of Liver Disease Severity in Patients With Known or Suspected Chronic Liver Disease,Not yet recruiting,Not Applicable,1000,1,Ultrasound liver assessment
NCT05090111,Aligos Therapeutics,01-DEC-21,30-SEP-22,Interventional,,A Study of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia,"A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Doses of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia, and an Open-Label Assessment of Bioavailability and Food-effect in Healthy Volunteers",Recruiting,Phase 1,152,2,ALG-055009|Placebo
NCT05203237,"Viking Therapeutics, Inc.",14-DEC-21,31-DEC-22,Interventional,,Phase 1 Study to Evaluate the Safety and Tolerability of VK2735,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VK2735, a Dual Glucagon-like Peptide-1 and Gastric Inhibitory Polypeptide Receptor Agonist, in Healthy Adults and Otherwise Healthy Adults Who Have an Increased Body Mass Index",Recruiting,Phase 1,88,4,VK2735|Placebo
NCT05195944,Novo Nordisk A/S,30-APR-22,31-DEC-24,Interventional,,Semaglutide vs Sitagliptin,"The GLP-1 Agonist Semaglutide for the Treatment of Metabolic Disease in Liver Transplant Recipients: A Phase IV, Randomized Trial",Not yet recruiting,Phase 4,140,2,Semaglutide Treatment|Sitagliptin 100mg
NCT05211284,Zydus Therapeutics Inc.,01-JUL-22,01-MAR-25,Interventional,,Saroglitazar Magnesium 4 mg for NASH in People Living With HIV in the US,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis (NASH) in People Living With Human Immunodeficiency Virus (HIV) in the US",Not yet recruiting,Phase 2,160,2,Saroglitazar Magnesium 4 mg|Placebo
NCT05292911,"Altimmune, Inc.",31-MAR-22,31-OCT-22,Interventional,,Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD),A 12-Week Extension Study of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD),Recruiting,Phase 1,60,4,ALT-801|Placebo
NCT05232071,Inventiva Pharma,01-JUN-22,01-JUL-23,Interventional,,"Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus","A Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With the Sodium-glucose Transport Protein 2 (SGLT2) Inhibitor EmpaGliflozin in patiEnts With Non-alcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)",Not yet recruiting,Phase 2,63,3,IVA337|Placebo|Empagliflozin
NCT05294458,AstraZeneca|Quotient Sciences,28-MAR-22,19-MAY-22,Interventional,,"A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy Subjects","A Single Part, Three-Way Crossover, Randomised, Open-Label Study Designed to Evaluate the Relative and Absolute Bioavailability Following a Single Subcutaneous Injection of a Novel High Concentration Subcutaneous Formulation of Cotadutide Against a Low Concentration Subcutaneous Formulation and Intravenous (IV) Formulation for Reference, in Healthy Subjects",Recruiting,Phase 1,12,1,cotadutide solution for injection
NCT05320146,Corcept Therapeutics,04-MAR-22,30-NOV-22,Observational,,"A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)","A Phase 1b, Open-Label Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Adult Patients With Presumed Nonalcoholic Steatohepatitis (NASH)",Recruiting,,36,,MRI-PDFF
NCT05357248,Better Therapeutics,10-APR-22,31-AUG-22,Interventional,,Nutritional Cognitive Behavioral Therapy Feasibility Study in NAFLD and NASH,Nutritional Cognitive Behavioral Therapy Feasibility Study in NAFLD and NASH,Enrolling by invitation,Not Applicable,20,1,BT-NCBT-00X
NCT05364931,AstraZeneca,19-MAY-22,08-MAY-25,Interventional,,A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis.,"A Phase IIb/III Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis",Not yet recruiting,Phase 2/Phase 3,1860,4,Cotadutide|Placebo
NCT05370053,Gilead Sciences,01-SEP-20,01-DEC-22,Interventional,,The Availability of the Enhanced Liver Fibrosis (ELF) Test Affects the Rate of Diagnosis of Nonalcoholic Steatohepatitis (NASH) With Fibrosis in Patients Referred to Hepatology,The Availability of the Enhanced Liver Fibrosis (ELF) Test Affects the Rate of Diagnosis of Nonalcoholic Steatohepatitis (NASH) With Fibrosis in Patients Referred to Hepatology,Recruiting,Not Applicable,450,2,ELF Test
